<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37175942</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>04</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Endotheliopathy in Acute COVID-19 and Long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">8237</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24098237</ELocationID><Abstract><AbstractText>The pulmonary endothelium is a highly regulated organ that performs a wide range of functions under physiological and pathological conditions. Since endothelial dysfunction has been demonstrated to play a direct role in sepsis and acute respiratory distress syndrome, its role in COVID-19 has also been extensively investigated. Indeed, apart from the COVID-19-associated coagulopathy biomarkers, new biomarkers were recognised early during the pandemic, including markers of endothelial cell activation or injury. We systematically searched the literature up to 10 March 2023 for studies examining the association between acute and long COVID-19 severity and outcomes and endothelial biomarkers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vassiliou</LastName><ForeName>Alice G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0003-4984-0476</Identifier><AffiliationInfo><Affiliation>First Department of Critical Care Medicine &amp; Pulmonary Services, School of Medicine, National and Kapodistrian University of Athens, Evangelismos Hospital, 106 76 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vrettou</LastName><ForeName>Charikleia S</ForeName><Initials>CS</Initials><Identifier Source="ORCID">0000-0002-1067-8849</Identifier><AffiliationInfo><Affiliation>First Department of Critical Care Medicine &amp; Pulmonary Services, School of Medicine, National and Kapodistrian University of Athens, Evangelismos Hospital, 106 76 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keskinidou</LastName><ForeName>Chrysi</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4047-3588</Identifier><AffiliationInfo><Affiliation>First Department of Critical Care Medicine &amp; Pulmonary Services, School of Medicine, National and Kapodistrian University of Athens, Evangelismos Hospital, 106 76 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimopoulou</LastName><ForeName>Ioanna</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-2219-7292</Identifier><AffiliationInfo><Affiliation>First Department of Critical Care Medicine &amp; Pulmonary Services, School of Medicine, National and Kapodistrian University of Athens, Evangelismos Hospital, 106 76 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotanidou</LastName><ForeName>Anastasia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>First Department of Critical Care Medicine &amp; Pulmonary Services, School of Medicine, National and Kapodistrian University of Athens, Evangelismos Hospital, 106 76 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orfanos</LastName><ForeName>Stylianos E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>First Department of Critical Care Medicine &amp; Pulmonary Services, School of Medicine, National and Kapodistrian University of Athens, Evangelismos Hospital, 106 76 Athens, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014652" MajorTopicYN="Y">Vascular Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">endotheliopathy</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. </CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>13</Day><Hour>15</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>13</Day><Hour>1</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37175942</ArticleId><ArticleId IdType="pmc">PMC10179170</ArticleId><ArticleId IdType="doi">10.3390/ijms24098237</ArticleId><ArticleId IdType="pii">ijms24098237</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cojocaru C., Cojocaru E., T urcanu A.M., Zaharia D.C. Clinical challenges of SARS-CoV-2 variants (Review) Exp. Ther. Med. 2022;23:416. doi: 10.3892/etm.2022.11343.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2022.11343</ArticleId><ArticleId IdType="pmc">PMC9117961</ArticleId><ArticleId IdType="pubmed">35601074</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur P., Thakur V., Kumar P., Patel S.K.S. Emergence of novel omicron hybrid variants: BA(x), XE, XD, XF more than just alphabets. Int. J. Surg. 2022;104:106727. doi: 10.1016/j.ijsu.2022.106727.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2022.106727</ArticleId><ArticleId IdType="pmc">PMC9225928</ArticleId><ArticleId IdType="pubmed">35753656</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur V., Bhola S., Thakur P., Patel S.K.S., Kulshrestha S., Ratho R.K., Kumar P. Waves and variants of SARS-CoV-2: Understanding the causes and effect of the COVID-19 catastrophe. Infection. 2021;50:309&#x2013;325. doi: 10.1007/s15010-021-01734-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01734-2</ArticleId><ArticleId IdType="pmc">PMC8675301</ArticleId><ArticleId IdType="pubmed">34914036</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassiliou A.G., Kotanidou A., Dimopoulou I., Orfanos S.E. Endothelial Damage in Acute Respiratory Distress Syndrome. Int. J. Mol. Sci. 2020;21:8793. doi: 10.3390/ijms21228793.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21228793</ArticleId><ArticleId IdType="pmc">PMC7699909</ArticleId><ArticleId IdType="pubmed">33233715</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorog D.A., Storey R.F., Gurbel P.A., Tantry U.S., Berger J.S., Chan M.Y., Duerschmied D., Smyth S.S., Parker W.A.E., Ajjan R.A., et al. Current and novel biomarkers of thrombotic risk in COVID-19: A Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nat. Rev. Cardiol. 2022;19:475&#x2013;495. doi: 10.1038/s41569-021-00665-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-021-00665-7</ArticleId><ArticleId IdType="pmc">PMC8757397</ArticleId><ArticleId IdType="pubmed">35027697</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2021;22:e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G., Maes M. Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics. BMC Med. 2013;11:205. doi: 10.1186/1741-7015-11-205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-11-205</ArticleId><ArticleId IdType="pmc">PMC3847236</ArticleId><ArticleId IdType="pubmed">24229326</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukriti S., Tauseef M., Yazbeck P., Mehta D. Mechanisms Regulating Endothelial Permeability. Pulm. Circ. 2014;4:535&#x2013;551. doi: 10.1086/677356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/677356</ArticleId><ArticleId IdType="pmc">PMC4278616</ArticleId><ArticleId IdType="pubmed">25610592</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartsock A., Nelson W.J. Adherens and tight junctions: Structure, function and connections to the actin cytoskeleton. Biochim. Biophys. Acta (BBA)-Biomembr. 2008;1778:660&#x2013;669. doi: 10.1016/j.bbamem.2007.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamem.2007.07.012</ArticleId><ArticleId IdType="pmc">PMC2682436</ArticleId><ArticleId IdType="pubmed">17854762</ArticleId></ArticleIdList></Reference><Reference><Citation>Herv&#xe9; J.-C., Derangeon M. Gap-junction-mediated cell-to-cell communication. Cell Tissue Res. 2012;352:21&#x2013;31. doi: 10.1007/s00441-012-1485-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-012-1485-6</ArticleId><ArticleId IdType="pubmed">22940728</ArticleId></ArticleIdList></Reference><Reference><Citation>Flemming S., Burkard N., Renschler M., Vielmuth F., Meir M., Schick M.A., Wunder C., Germer C.-T., Spindler V., Waschke J., et al. Soluble VE-cadherin is involved in endothelial barrier breakdown in systemic inflammation and sepsis. Cardiovasc. Res. 2015;107:32&#x2013;44. doi: 10.1093/cvr/cvv144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvv144</ArticleId><ArticleId IdType="pubmed">25975259</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu W.-K., McNeil J.B., Wickersham N.E., Shaver C.M., Bastarache J.A., Ware L.B. Vascular endothelial cadherin shedding is more severe in sepsis patients with severe acute kidney injury. Crit. Care. 2019;23:18. doi: 10.1186/s13054-019-2315-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2315-y</ArticleId><ArticleId IdType="pmc">PMC6339439</ArticleId><ArticleId IdType="pubmed">30658667</ArticleId></ArticleIdList></Reference><Reference><Citation>Michalick L., Weidenfeld S., Grimmer B., Fatykhova D., Solymosi P.D., Behrens F., Dohmen M., Brack M.C., Schulz S., Thomasch E., et al. Plasma mediators in patients with severe COVID-19 cause lung endothelial barrier failure. Eur. Respir. J. 2020;57:2002384. doi: 10.1183/13993003.02384-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02384-2020</ArticleId><ArticleId IdType="pmc">PMC7651836</ArticleId><ArticleId IdType="pubmed">33154030</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassiliou A.G., Keskinidou C., Jahaj E., Gallos P., Dimopoulou I., Kotanidou A., Orfanos S.E. ICU Admission Levels of Endothelial Biomarkers as Predictors of Mortality in Critically Ill COVID-19 Patients. Cells. 2021;10:186. doi: 10.3390/cells10010186.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10010186</ArticleId><ArticleId IdType="pmc">PMC7832393</ArticleId><ArticleId IdType="pubmed">33477776</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel M.A., Knauer M.J., Nicholson M., Daley M., Van Nynatten L.R., Martin C., Patterson E.K., Cepinskas G., Seney S.L., Dobretzberger V., et al. Elevated vascular transformation blood biomarkers in Long-COVID indicate angiogenesis as a key pathophysiological mechanism. Mol. Med. 2022;28:122. doi: 10.1186/s10020-022-00548-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-022-00548-8</ArticleId><ArticleId IdType="pmc">PMC9549814</ArticleId><ArticleId IdType="pubmed">36217108</ArticleId></ArticleIdList></Reference><Reference><Citation>Brindle N.P.J., Saharinen P., Alitalo K. Signaling and Functions of Angiopoietin-1 in Vascular Protection. Circ. Res. 2006;98:1014&#x2013;1023. doi: 10.1161/01.RES.0000218275.54089.12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.0000218275.54089.12</ArticleId><ArticleId IdType="pmc">PMC2270395</ArticleId><ArticleId IdType="pubmed">16645151</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemieux C., Maliba R., Favier J., Th&#xe9;or&#xea;t J.-F., Merhi Y., Sirois M.G. Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses. Blood. 2005;105:1523&#x2013;1530. doi: 10.1182/blood-2004-09-3531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2004-09-3531</ArticleId><ArticleId IdType="pubmed">15498854</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou-Arab O., Bennis Y., Gauthier P., Boudot C., Bourdenet G., Gubler B., Beyls C., Dupont H., Kamel S., Mahjoub Y. Association between inflammation, angiopoietins, and disease severity in critically ill COVID-19 patients: A prospective study. Br. J. Anaesth. 2020;126:e127&#x2013;e130. doi: 10.1016/j.bja.2020.12.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bja.2020.12.017</ArticleId><ArticleId IdType="pmc">PMC7755573</ArticleId><ArticleId IdType="pubmed">33423740</ArticleId></ArticleIdList></Reference><Reference><Citation>Smadja D.M., Guerin C.L., Chocron R., Yatim N., Boussier J., Gendron N., Khider L., Hadjadj J., Goudot G., Debuc B., et al. Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. Angiogenesis. 2020;23:611&#x2013;620. doi: 10.1007/s10456-020-09730-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10456-020-09730-0</ArticleId><ArticleId IdType="pmc">PMC7250589</ArticleId><ArticleId IdType="pubmed">32458111</ArticleId></ArticleIdList></Reference><Reference><Citation>Pine A.B., Meizlish M.L., Goshua G., Chang C.H., Zhang H., Bishai J., Bahel P., Patel A., Gbyli R., Kwan J.M., et al. Circulating markers of angiogenesis and endotheliopathy in COVID-19. Pulm. Circ. 2020;10:966547. doi: 10.1177/2045894020966547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2045894020966547</ArticleId><ArticleId IdType="pmc">PMC7691906</ArticleId><ArticleId IdType="pubmed">33282193</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan L., Cheng S., Sol W.M., van der Velden A.I., Vink H., Rabelink T.J., Berg B.M.V.D. Heparan sulfate mimetic fucoidan restores the endothelial glycocalyx and protects against dysfunction induced by serum of COVID-19 patients in the intensive care unit. ERJ Open Res. 2022;8:00652&#x2013;2021. doi: 10.1183/23120541.00652-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00652-2021</ArticleId><ArticleId IdType="pmc">PMC8958944</ArticleId><ArticleId IdType="pubmed">35509442</ArticleId></ArticleIdList></Reference><Reference><Citation>Spadaro S., Fogagnolo A., Campo G., Zucchetti O., Verri M., Ottaviani I., Tunstall T., Grasso S., Scaramuzzo V., Murgolo F., et al. Markers of endothelial and epithelial pulmonary injury in mechanically ventilated COVID-19 ICU patients. Crit. Care. 2021;25:74. doi: 10.1186/s13054-021-03499-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-021-03499-4</ArticleId><ArticleId IdType="pmc">PMC7894238</ArticleId><ArticleId IdType="pubmed">33608030</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmaier A.A., Hurtado G.M.P., Manickas-Hill Z.J., Sack K.D., Chen S.M., Bhambhani V., Quadir J., Nath A.K., Collier A.-R.Y., Ngo D., et al. Tie2 activation protects against prothrombotic endothelial dysfunction in COVID-19. J. Clin. Investig. 2021;6:151527. doi: 10.1172/jci.insight.151527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.151527</ArticleId><ArticleId IdType="pmc">PMC8564889</ArticleId><ArticleId IdType="pubmed">34506304</ArticleId></ArticleIdList></Reference><Reference><Citation>Alay H., Laloglu E. The role of angiopoietin-2 and surfactant protein-D levels in SARS-CoV-2-related lung injury: A prospective, observational, cohort study. J. Med. Virol. 2021;93:6008&#x2013;6015. doi: 10.1002/jmv.27184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27184</ArticleId><ArticleId IdType="pmc">PMC8427084</ArticleId><ArticleId IdType="pubmed">34232533</ArticleId></ArticleIdList></Reference><Reference><Citation>Maldonado F., Morales D., D&#xed;az-Papapietro C., Vald&#xe9;s C., Fernandez C., Valls N., Lazo M., Espinoza C., Gonz&#xe1;lez R., Guti&#xe9;rrez R., et al. Relationship Between Endothelial and Angiogenesis Biomarkers Envisage Mortality in a Prospective Cohort of COVID-19 Patients Requiring Respiratory Support. Front. Med. 2022;9:826218. doi: 10.3389/fmed.2022.826218.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.826218</ArticleId><ArticleId IdType="pmc">PMC8966493</ArticleId><ArticleId IdType="pubmed">35372407</ArticleId></ArticleIdList></Reference><Reference><Citation>Hultstr&#xf6;m M., Fromell K., Larsson A., Persson B., Nilsson B., Quaggin S.E., Betsholtz C., Frithiof R., Lipcsey M., Jeansson M. Angiopoietin-2 Inhibition of Thrombomodulin-Mediated Anticoagulation&#x2014;A Novel Mechanism That May Contribute to Hypercoagulation in Critically Ill COVID-19 Patients. Biomedicines. 2022;10:1333. doi: 10.3390/biomedicines10061333.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10061333</ArticleId><ArticleId IdType="pmc">PMC9220312</ArticleId><ArticleId IdType="pubmed">35740360</ArticleId></ArticleIdList></Reference><Reference><Citation>Price D.R., Benedetti E., Hoffman K.L., Gomez-Escobar L., Alvarez-Mulett S., Capili A., Sarwath H., Parkhurst C.N., Lafond E., Weidman K., et al. Angiopoietin 2 Is Associated with Vascular Necroptosis Induction in Coronavirus Disease 2019 Acute Respiratory Distress Syndrome. Am. J. Pathol. 2022;192:1001&#x2013;1015. doi: 10.1016/j.ajpath.2022.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2022.04.002</ArticleId><ArticleId IdType="pmc">PMC9027298</ArticleId><ArticleId IdType="pubmed">35469796</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones R.S., Smith P.S., Berg P.H., de la Pe&#xf1;a A., Cook P.P., Shawa I., Kioussopoulos K.M., Hu Y., Schott R.J. Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19. Clin. Med. Insights Circ. Respir. Pulm. Med. 2022;16:11795484221119316. doi: 10.1177/11795484221119316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/11795484221119316</ArticleId><ArticleId IdType="pmc">PMC9382233</ArticleId><ArticleId IdType="pubmed">35991210</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibila O., Perea L., Albacar N., Mois&#xe9;s J., Cruz T., Mendoza N., Solarat B., Lled&#xf3; G., Espinosa G., Barber&#xe0; J.A., et al. Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge. Respir. Res. 2022;23:37. doi: 10.1186/s12931-022-01955-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-022-01955-5</ArticleId><ArticleId IdType="pmc">PMC8860292</ArticleId><ArticleId IdType="pubmed">35189887</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H., Ward S.E., Townsend L., Karampini E., Elliott S., Conlon N., Dunne J., Kiersey R., Naughton A., Gardiner M., et al. Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction. J. Thromb. Haemost. 2022;20:2429&#x2013;2438. doi: 10.1111/jth.15830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15830</ArticleId><ArticleId IdType="pmc">PMC9349977</ArticleId><ArticleId IdType="pubmed">35875995</ArticleId></ArticleIdList></Reference><Reference><Citation>Haffke M., Freitag H., Rudolf G., Seifert M., Doehner W., Scherbakov N., Hanitsch L., Wittke K., Bauer S., Konietschke F., et al. Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS) J. Transl. Med. 2022;20:138. doi: 10.1186/s12967-022-03346-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03346-2</ArticleId><ArticleId IdType="pmc">PMC8938726</ArticleId><ArticleId IdType="pubmed">35317812</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitsma S., Slaaf D.W., Vink H., van Zandvoort M.A.M.J., Oude Egbrink M.G. The endothelial glycocalyx: Composition, functions, and visualization. Pflug. Arch. Eur. J. Physiol. 2007;454:345&#x2013;359. doi: 10.1007/s00424-007-0212-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00424-007-0212-8</ArticleId><ArticleId IdType="pmc">PMC1915585</ArticleId><ArticleId IdType="pubmed">17256154</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatti M.N., Fabro A.T., Miranda C.H. Endothelial glycocalyx shedding in the acute respiratory distress syndrome after flu syndrome. J. Intensiv. Care. 2020;8:72. doi: 10.1186/s40560-020-00488-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40560-020-00488-7</ArticleId><ArticleId IdType="pmc">PMC7503444</ArticleId><ArticleId IdType="pubmed">32974033</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng Y.H.-F., Aquino R.S., Park P.W. Molecular functions of syndecan-1 in disease. Matrix Biol. 2012;31:3&#x2013;16. doi: 10.1016/j.matbio.2011.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2011.10.001</ArticleId><ArticleId IdType="pmc">PMC3568394</ArticleId><ArticleId IdType="pubmed">22033227</ArticleId></ArticleIdList></Reference><Reference><Citation>Goonewardena S.N., Grushko O.G., Wells J., Herty L., Rosenson R.S., Haus J.M., Hummel S.L. Immune-Mediated Glycocalyx Remodeling in Hospitalized COVID-19 Patients. Cardiovasc. Drugs Ther. 2021;37:307&#x2013;313. doi: 10.1007/s10557-021-07288-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10557-021-07288-7</ArticleId><ArticleId IdType="pmc">PMC8600103</ArticleId><ArticleId IdType="pubmed">34792686</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarraj J., Park E.S., Colpo G.D., Hinds S.N., Morales D., Ahnstedt H., Paz A.S., Assing A., Liu F., Juneja S., et al. Brain injury, endothelial injury and inflammatory markers are elevated and express sex-specific alterations after COVID-19. J. Neuroinflammation. 2021;18:277. doi: 10.1186/s12974-021-02323-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-021-02323-8</ArticleId><ArticleId IdType="pmc">PMC8627162</ArticleId><ArticleId IdType="pubmed">34838058</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Ye Z., McGowan P., Jurief C., Ly A., Bignotti A., Yada N., Zheng X.L. Effects of convalescent plasma infusion on the ADAMTS13-von Willebrand factor axis and endothelial integrity in patients with severe and critical COVID-19. Res. Pract. Thromb. Haemost. 2023;7:100010. doi: 10.1016/j.rpth.2022.100010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rpth.2022.100010</ArticleId><ArticleId IdType="pmc">PMC9744678</ArticleId><ArticleId IdType="pubmed">36531671</ArticleId></ArticleIdList></Reference><Reference><Citation>Karampoor S., Zahednasab H., Farahmand M., Mirzaei R., Zamani F., Tabibzadeh A., Bouzari B., Ajdarkosh H., Nikkhah M., Hashemi M.R., et al. A possible pathogenic role of Syndecan-1 in the pathogenesis of coronavirus disease 2019 (COVID-19) Int. Immunopharmacol. 2021;97:107684. doi: 10.1016/j.intimp.2021.107684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.107684</ArticleId><ArticleId IdType="pmc">PMC8052477</ArticleId><ArticleId IdType="pubmed">33932696</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa F., Oi Y., Nakajima K., Matsumura R., Nakagawa T., Miyagawa T., Sakai K., Saji R., Taniguchi H., Takahashi K., et al. Temporal change in Syndecan-1 as a therapeutic target and a biomarker for the severity classification of COVID-19. Thromb. J. 2021;19:55. doi: 10.1186/s12959-021-00308-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12959-021-00308-4</ArticleId><ArticleId IdType="pmc">PMC8366156</ArticleId><ArticleId IdType="pubmed">34399775</ArticleId></ArticleIdList></Reference><Reference><Citation>Mungu&#xed;a L., N&#xe1;jera N., Mart&#xed;nez F.D.J., D&#xed;az-Chiguer D., Jim&#xe9;nez-Ponce F., Ortiz-Flores M., Villarreal F., Ceballos G. Correlation of Biomarkers of Endothelial Injury and Inflammation to Outcome in Hospitalized COVID-19 Patients. J. Clin. Med. 2022;11:7436. doi: 10.3390/jcm11247436.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11247436</ArticleId><ArticleId IdType="pmc">PMC9785942</ArticleId><ArticleId IdType="pubmed">36556051</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W.-Y., Kweon O.J., Cha M.J., Baek M.S., Choi S.-H. Dexamethasone may improve severe COVID-19 via ameliorating endothelial injury and inflammation: A preliminary pilot study. PLoS ONE. 2021;16:e0254167. doi: 10.1371/journal.pone.0254167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0254167</ArticleId><ArticleId IdType="pmc">PMC8253399</ArticleId><ArticleId IdType="pubmed">34214123</ArticleId></ArticleIdList></Reference><Reference><Citation>Mobayen G., Dhutia A., Clarke C., Prendecki M., McAdoo S., Msc R.K., Malik T., Laffan M., Willicombe M., McKinnon T. Severe COVID-19 is associated with endothelial activation and abnormal glycosylation of von Willebrand factor in patients undergoing hemodialysis. Res. Pract. Thromb. Haemost. 2021;5:e12582. doi: 10.1002/rth2.12582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12582</ArticleId><ArticleId IdType="pmc">PMC8435526</ArticleId><ArticleId IdType="pubmed">34532629</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D., Li L., Chen Y., Ma J., Yang Y., Aodeng S., Cui Q., Wen K., Xiao M., Xie J., et al. Syndecan-1, an indicator of endothelial glycocalyx degradation, predicts outcome of patients admitted to an ICU with COVID-19. Mol. Med. 2021;27:151. doi: 10.1186/s10020-021-00412-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-021-00412-1</ArticleId><ArticleId IdType="pmc">PMC8640509</ArticleId><ArticleId IdType="pubmed">34861818</ArticleId></ArticleIdList></Reference><Reference><Citation>Astapenko D., Tomasova A., Ticha A., Hyspler R., Chua H.S., Manzoor M., Skulec R., Lehmann C., Hahn R.G., Malbrain M.L., et al. Endothelial glycocalyx damage in patients with severe COVID-19 on mechanical ventilation&#x2014;A prospective observational pilot study. Clin. Hemorheol. Microcirc. 2022;81:205&#x2013;219. doi: 10.3233/CH-221401.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/CH-221401</ArticleId><ArticleId IdType="pubmed">35342082</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollenberg R., Tepasse P.-R., Ochs K., Floer M., Strauss M., Rennebaum F., Kabar I., Rovas A., Nowacki T. Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis. Viruses. 2021;13:2324. doi: 10.3390/v13112324.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13112324</ArticleId><ArticleId IdType="pmc">PMC8619155</ArticleId><ArticleId IdType="pubmed">34835130</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetland G., Fagerhol M.K., Dimova-Svetoslavova V.P., Mirlashari M.R., Nguyen N.T., Lind A., Kolset S.O., S&#xf8;raas A.V.L., Nissen-Meyer L.S.H. Inflammatory markers calprotectin, NETs, syndecan-1 and neopterin in COVID-19 convalescent blood donors. Scand. J. Clin. Lab. Investig. 2022;82:481&#x2013;485. doi: 10.1080/00365513.2022.2123387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365513.2022.2123387</ArticleId><ArticleId IdType="pubmed">36151851</ArticleId></ArticleIdList></Reference><Reference><Citation>Koz&#x142;owski P., &#x15a;miarowski M., Przyborska W., Zemlik K., Ma&#x142;ecka-Gie&#x142;dowska M., Leszczy&#x144;ska A., Garley M., Ciepiela O. Mild-to-Moderate COVID-19 Convalescents May Present Pro-Longed Endothelium Injury. J. Clin. Med. 2022;11:6461. doi: 10.3390/jcm11216461.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11216461</ArticleId><ArticleId IdType="pmc">PMC9658558</ArticleId><ArticleId IdType="pubmed">36362687</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;chard D., Gentina T., Delehedde M., Scherpereel A., Lyon M., Aumercier M., Vazeux R., Richet C., Degand P., Jude B., et al. Endocan Is a Novel Chondroitin Sulfate/Dermatan Sulfate Proteoglycan That Promotes Hepatocyte Growth Factor/Scatter Factor Mitogenic Activity. J. Biol. Chem. 2001;276:48341&#x2013;48349. doi: 10.1074/jbc.M108395200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M108395200</ArticleId><ArticleId IdType="pubmed">11590178</ArticleId></ArticleIdList></Reference><Reference><Citation>Orbegozo D., Rahmania L.L., Irazabal M.M., Mendoza M.M., Annoni F., De Backer D., Creteur J., Vincent J.-L. Endocan as an early biomarker of severity in patients with acute respiratory distress syndrome. Ann. Intensiv. Care. 2017;7:93. doi: 10.1186/s13613-017-0311-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-017-0311-4</ArticleId><ArticleId IdType="pmc">PMC5589715</ArticleId><ArticleId IdType="pubmed">28884313</ArticleId></ArticleIdList></Reference><Reference><Citation>Caires N.D.F., Gaudet A., Portier L., Tsicopoulos A., Mathieu D., Lassalle P. Endocan, sepsis, pneumonia, and acute respiratory distress syndrome. Crit. Care. 2018;22:280. doi: 10.1186/s13054-018-2222-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-018-2222-7</ArticleId><ArticleId IdType="pmc">PMC6204032</ArticleId><ArticleId IdType="pubmed">30367649</ArticleId></ArticleIdList></Reference><Reference><Citation>Keskinidou C., Vassiliou A.G., Zacharis A., Jahaj E., Gallos P., Dimopoulou I., Orfanos S.E., Kotanidou A. Endothelial, Immunothrombotic, and Inflammatory Biomarkers in the Risk of Mortality in Critically Ill COVID-19 Patients: The Role of Dexamethasone. Diagnostics. 2021;11:1249. doi: 10.3390/diagnostics11071249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11071249</ArticleId><ArticleId IdType="pmc">PMC8304647</ArticleId><ArticleId IdType="pubmed">34359331</ArticleId></ArticleIdList></Reference><Reference><Citation>Medetalibeyoglu A., Emet S., Kose M., Akpinar T.S., Senkal N., Catma Y., Kaytaz A.M., Genc S., Omer B., Tukek T. Serum Endocan Levels on Admission Are Associated with Worse Clinical Outcomes in COVID-19 Patients: A Pilot Study. Angiology. 2020;72:187&#x2013;193. doi: 10.1177/0003319720961267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0003319720961267</ArticleId><ArticleId IdType="pubmed">32969233</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalaji A., Amirkhani N., Sharifkashani S., Peiman S., Behnoush A.H. Systematic Review of Endocan as a Potential Biomarker of COVID-19. Angiology. 2023 doi: 10.1177/00033197231152941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/00033197231152941</ArticleId><ArticleId IdType="pmc">PMC9895317</ArticleId><ArticleId IdType="pubmed">36680504</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton D.J., Kennedy G., Chan K.K., Lang C.C., Belch J.J., Khan F. Large and small artery endothelial dysfunction in chronic fatigue syndrome. Int. J. Cardiol. 2011;154:335&#x2013;336. doi: 10.1016/j.ijcard.2011.10.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2011.10.030</ArticleId><ArticleId IdType="pubmed">22078396</ArticleId></ArticleIdList></Reference><Reference><Citation>Zha D., Fu M., Qian Y. Vascular Endothelial Glycocalyx Damage and Potential Targeted Therapy in COVID-19. Cells. 2022;11:1972. doi: 10.3390/cells11121972.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11121972</ArticleId><ArticleId IdType="pmc">PMC9221624</ArticleId><ArticleId IdType="pubmed">35741101</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaoka-Tojo M. Endothelial glycocalyx damage as a systemic inflammatory microvascular endotheliopathy in COVID-19. Biomed. J. 2020;43:399&#x2013;413. doi: 10.1016/j.bj.2020.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bj.2020.08.007</ArticleId><ArticleId IdType="pmc">PMC7443638</ArticleId><ArticleId IdType="pubmed">33032965</ArticleId></ArticleIdList></Reference><Reference><Citation>LaRivi&#xe8;re W.B., Schmidt E.P. Current Topics in Membranes. Volume 82. Elsevier Inc.; Philadelphia, PA, USA: 2018. The Pulmonary Endothelial Glycocalyx in ARDS: A Critical Role for Heparan Sulfate; pp. 33&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.ctm.2018.08.005</ArticleId><ArticleId IdType="pubmed">30360782</ArticleId></ArticleIdList></Reference><Reference><Citation>Potje S.R., Costa T.J., Fraga-Silva T.F., Martins R.B., Benatti M.N., Almado C.E., de S&#xe1; K.S., Bonato V.L., Arruda E., Louzada-Junior P., et al. Heparin prevents in vitro glycocalyx shedding induced by plasma from COVID-19 patients. Life Sci. 2021;276:119376. doi: 10.1016/j.lfs.2021.119376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2021.119376</ArticleId><ArticleId IdType="pmc">PMC7997864</ArticleId><ArticleId IdType="pubmed">33781826</ArticleId></ArticleIdList></Reference><Reference><Citation>Montazersaheb S., Khatibi S.M.H., Hejazi M.S., Tarhriz V., Farjami A., Sorbeni F.G., Farahzadi R., Ghasemnejad T. COVID-19 infection: An overview on cytokine storm and related interventions. Virol. J. 2022;19:92. doi: 10.1186/s12985-022-01814-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01814-1</ArticleId><ArticleId IdType="pmc">PMC9134144</ArticleId><ArticleId IdType="pubmed">35619180</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Huang S., Yin L. The cytokine storm and COVID-19. J. Med. Virol. 2020;93:250&#x2013;256. doi: 10.1002/jmv.26232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26232</ArticleId><ArticleId IdType="pmc">PMC7361342</ArticleId><ArticleId IdType="pubmed">32592501</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanza C., Romenskaya T., Manetti A.C., Franceschi F., La Russa R., Bertozzi G., Maiese A., Savioli G., Volonnino G., Longhitano Y. Cytokine Storm in COVID-19: Immunopathogenesis and Therapy. Medicina. 2022;58:144. doi: 10.3390/medicina58020144.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina58020144</ArticleId><ArticleId IdType="pmc">PMC8876409</ArticleId><ArticleId IdType="pubmed">35208467</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahamed J., Laurence J. Long COVID endotheliopathy: Hypothesized mechanisms and potential therapeutic approaches. J. Clin. Investig. 2022;132:e161167. doi: 10.1172/JCI161167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI161167</ArticleId><ArticleId IdType="pmc">PMC9337829</ArticleId><ArticleId IdType="pubmed">35912863</ArticleId></ArticleIdList></Reference><Reference><Citation>McEver R.P. Selectins: Initiators of leucocyte adhesion and signalling at the vascular wall. Cardiovasc. Res. 2015;107:331&#x2013;339. doi: 10.1093/cvr/cvv154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvv154</ArticleId><ArticleId IdType="pmc">PMC4592324</ArticleId><ArticleId IdType="pubmed">25994174</ArticleId></ArticleIdList></Reference><Reference><Citation>Gearing A.J.H., Hemingway I., Pigoit R., Hughes J., Rees A.J., Cashman S.J. Soluble Forms of Vascular Adhesion Molecules, E-Selectin, ICAM-1, and VCAM-1: Pathological Significance. Ann. N. Y. Acad. Sci. 1992;667:324&#x2013;331. doi: 10.1111/j.1749-6632.1992.tb51633.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1992.tb51633.x</ArticleId><ArticleId IdType="pubmed">1285023</ArticleId></ArticleIdList></Reference><Reference><Citation>Birnhuber A., Fliesser E., Gorkiewicz G., Zacharias M., Seeliger B., David S., Welte T., Schmidt J., Olschewski H., Wygrecka M., et al. Between inflammation and thrombosis: Endothelial cells in COVID-19. Eur. Respir. J. 2021;58:2100377. doi: 10.1183/13993003.00377-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00377-2021</ArticleId><ArticleId IdType="pmc">PMC8112008</ArticleId><ArticleId IdType="pubmed">33958433</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu N., Long H., Sun J., Li H., He Y., Wang Q., Pan K., Tong Y., Wang B., Wu Q., et al. New laboratory evidence for the association between endothelial dysfunction and COVID-19 disease progression. J. Med. Virol. 2022;94:3112&#x2013;3120. doi: 10.1002/jmv.27693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27693</ArticleId><ArticleId IdType="pmc">PMC9088409</ArticleId><ArticleId IdType="pubmed">35246853</ArticleId></ArticleIdList></Reference><Reference><Citation>Watany M.M., Abdou S., Elkolaly R., Elgharbawy N., Hodeib H. Evaluation of admission levels of P, E and L selectins as predictors for thrombosis in hospitalized COVID-19 patients. Clin. Exp. Med. 2022;22:567&#x2013;575. doi: 10.1007/s10238-021-00787-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-021-00787-9</ArticleId><ArticleId IdType="pmc">PMC8778493</ArticleId><ArticleId IdType="pubmed">35061142</ArticleId></ArticleIdList></Reference><Reference><Citation>Cugno M., Meroni P.L., Gualtierotti R., Griffini S., Grovetti E., Torri A., Lonati P., Grossi C., Borghi M.O., Novembrino C., et al. Complement activation and endothelial perturbation parallel COVID-19 severity and activity. J. Autoimmun. 2020;116:102560. doi: 10.1016/j.jaut.2020.102560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102560</ArticleId><ArticleId IdType="pmc">PMC7598768</ArticleId><ArticleId IdType="pubmed">33139116</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezine F., Guerin C.L., Philippe A., Gendron N., Soret L., Sanchez O., Mirault T., Diehl J.-L., Chocron R., Boulanger C.M., et al. Increased Circulating CD62E+ Endothelial Extracellular Vesicles Predict Severity and in- Hospital Mortality of COVID-19 Patients. Stem Cell Rev. Rep. 2022;19:114&#x2013;119. doi: 10.1007/s12015-022-10446-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12015-022-10446-5</ArticleId><ArticleId IdType="pmc">PMC9387889</ArticleId><ArticleId IdType="pubmed">35982357</ArticleId></ArticleIdList></Reference><Reference><Citation>Orea-Tejada A., S&#xe1;nchez-Moreno C., Aztatzi-Aguilar O.G., Sierra-Vargas M.P., Gonz&#xe1;lez-Islas D., Debray-Garc&#xed;a Y., Ortega-Romero M.S., Keirns-Davis C., Cornejo-Cornejo L., Aguilar-Meza J. Plasma Endothelial and Oxidative Stress Biomarkers Associated with Late Mortality in Hospitalized COVID-19 Patients. J. Clin. Med. 2022;11:3950. doi: 10.3390/jcm11143950.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11143950</ArticleId><ArticleId IdType="pmc">PMC9319197</ArticleId><ArticleId IdType="pubmed">35887714</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliva A., Rando E., Al Ismail D., De Angelis M., Cancelli F., Miele M.C., Aronica R., Mauro V., Di Timoteo F., Loffredo L., et al. Role of Serum E-Selectin as a Biomarker of Infection Severity in Coronavirus Disease 2019. J. Clin. Med. 2021;10:4018. doi: 10.3390/jcm10174018.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10174018</ArticleId><ArticleId IdType="pmc">PMC8432564</ArticleId><ArticleId IdType="pubmed">34501466</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochoa C., Wu S., Stevens T. New Developments in Lung Endothelial Heterogeneity: Von Willebrand Factor, P-Selectin, and the Weibel-Palade Body. Semin. Thromb. Hemost. 2010;36:301&#x2013;308. doi: 10.1055/s-0030-1253452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0030-1253452</ArticleId><ArticleId IdType="pmc">PMC2917989</ArticleId><ArticleId IdType="pubmed">20490980</ArticleId></ArticleIdList></Reference><Reference><Citation>Goshua G., Pine A.B., Meizlish M.L., Chang C.-H., Zhang H., Bahel P., Baluha A., Bar N., Bona R.D., Burns A.J., et al. Endotheliopathy in COVID-19-associated coagulopathy: Evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020;7:e575&#x2013;e582. doi: 10.1016/S2352-3026(20)30216-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(20)30216-7</ArticleId><ArticleId IdType="pmc">PMC7326446</ArticleId><ArticleId IdType="pubmed">32619411</ArticleId></ArticleIdList></Reference><Reference><Citation>Osburn W.O., Smith K., Yanek L., Amat-Alcaron N., Thiemann D.R., Cox A.L., Leucker T.M., Lowenstein C.J. Markers of endothelial cell activation are associated with the severity of pulmonary disease in COVID-19. PLoS ONE. 2022;17:e0268296. doi: 10.1371/journal.pone.0268296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0268296</ArticleId><ArticleId IdType="pmc">PMC9119480</ArticleId><ArticleId IdType="pubmed">35588115</ArticleId></ArticleIdList></Reference><Reference><Citation>Yatim N., Boussier J., Chocron R., Hadjadj J., Philippe A., Gendron N., Barnabei L., Charbit B., Szwebel T.-A., Carlier N., et al. Platelet activation in critically ill COVID-19 patients. Ann. Intensiv. Care. 2021;11:113. doi: 10.1186/s13613-021-00899-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-021-00899-1</ArticleId><ArticleId IdType="pmc">PMC8286043</ArticleId><ArticleId IdType="pubmed">34273008</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett T.J., Lee A.H., Xia Y., Lin L.H., Black M., Cotzia P., Hochman J., Berger J.S. Platelet and Vascular Biomarkers Associate with Thrombosis and Death in Coronavirus Disease. Circ. Res. 2020;127:945&#x2013;947. doi: 10.1161/CIRCRESAHA.120.317803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.317803</ArticleId><ArticleId IdType="pmc">PMC7478197</ArticleId><ArticleId IdType="pubmed">32757722</ArticleId></ArticleIdList></Reference><Reference><Citation>Eldahshan M., Byomy M., Alsadek A., Hassan M., Eltrawy H., Abdelwahab M., Ali W., Eliwa A. Prognostic Significance of Platelet Activation Marker CD62P in Hospitalized Covid-19 Patients. Clin. Lab. 2022;68:211201. doi: 10.7754/Clin.Lab.2022.211201.</Citation><ArticleIdList><ArticleId IdType="doi">10.7754/Clin.Lab.2022.211201</ArticleId><ArticleId IdType="pubmed">36125149</ArticleId></ArticleIdList></Reference><Reference><Citation>Farouk N., Ashry W.M.O., El-Hagrasy H.A., Mohamed E.F., Eltrawy H.H., El-Nasser A.M., Shipl W., El Attar S., Sakr L.K., Wahab M.A.A., et al. Admission Levels of Serum P-Selectin and IL-6 Can Predict Development of Deep Venous Thrombosis in Hospitalized Covid-19 Patients. Int. J. Gen. Med. 2022;15:5599&#x2013;5607. doi: 10.2147/IJGM.S357097.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S357097</ArticleId><ArticleId IdType="pmc">PMC9197170</ArticleId><ArticleId IdType="pubmed">35712059</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Ghani S.E.-S.A., Hamed R.M.R., Eid R.A., Ibrahim A.Y.M., Abdel-Hamid H.M., Abdelrahman W., Ibrahim R.E., Abdel-Aziz M.M., Mohamed M.S. Serum interleukin 1&#x3b2; and sP-selectin as biomarkers of inflammation and thrombosis, could they be predictors of disease severity in COVID 19 Egyptian patients? (a cross-sectional study) Thromb. J. 2022;20:77. doi: 10.1186/s12959-022-00428-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12959-022-00428-5</ArticleId><ArticleId IdType="pmc">PMC9754776</ArticleId><ArticleId IdType="pubmed">36522776</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenyves B.G., Mehta A., Kays K.R., Beakes C., Margolin J., Goldberg M.B., Hacohen N., Filbin M.R., MGH COVID-19 Collection &amp; Processing Team Plasma P-selectin is an early marker of thromboembolism in COVID-19. Am. J. Hematol. 2021;96:E468. doi: 10.1002/ajh.26372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26372</ArticleId><ArticleId IdType="pmc">PMC8616847</ArticleId><ArticleId IdType="pubmed">34622480</ArticleId></ArticleIdList></Reference><Reference><Citation>Venter C., Bezuidenhout J.A., Laubscher G.J., Lourens P.J., Steenkamp J., Kell D.B., Pretorius E. Erythrocyte, Platelet, Serum Ferritin, and P-Selectin Pathophysiology Implicated in Severe Hypercoagulation and Vascular Complications in COVID-19. Int. J. Mol. Sci. 2020;21:8234. doi: 10.3390/ijms21218234.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21218234</ArticleId><ArticleId IdType="pmc">PMC7662625</ArticleId><ArticleId IdType="pubmed">33153161</ArticleId></ArticleIdList></Reference><Reference><Citation>Elhadad S., Redmond D., Tan A., Huang J., Rodriguez B.L., Racine-Brzostek S.E., Subrahmanian S., Ahamed J., Laurence J. Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies. Thromb. Res. 2023;225:47&#x2013;56. doi: 10.1016/j.thromres.2023.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2023.03.009</ArticleId><ArticleId IdType="pmc">PMC10033153</ArticleId><ArticleId IdType="pubmed">37001283</ArticleId></ArticleIdList></Reference><Reference><Citation>Reutershan J., Ley K. Bench-to-bedside review: Acute respiratory distress syndrome&#x2014;How neutrophils migrate into the lung. Crit. Care. 2004;8:453&#x2013;461. doi: 10.1186/cc2881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc2881</ArticleId><ArticleId IdType="pmc">PMC1065041</ArticleId><ArticleId IdType="pubmed">15566616</ArticleId></ArticleIdList></Reference><Reference><Citation>Leucker T.M., Osburn W.O., Reventun P., Smith K., Claggett B., Kirwan B.-A., de Brouwer S., Williams M.S., Gerstenblith G., Hager D.N., et al. Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19. JACC Basic Transl. Sci. 2021;6:935&#x2013;945. doi: 10.1016/j.jacbts.2021.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacbts.2021.09.013</ArticleId><ArticleId IdType="pmc">PMC8653991</ArticleId><ArticleId IdType="pubmed">34904132</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner S., Naidoo C.A., Usher T.J., Kruger A., Venter C., Laubscher G.J., Khan M.A., Kell D.B., Pretorius E. Increased levels of inflammatory molecules in blood of Long COVID patients point to thrombotic endotheliitis. medRxiv. 2022.  [(accessed on 12 March 2023)].  
Pre-print
. Available online:  https://www.medrxiv.org/content/10.1101/2022.10.13.22281055v1.full.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.10.13.22281055v1.full</ArticleId><ArticleId IdType="doi">10.1101/2022.10.13.22281055</ArticleId><ArticleId IdType="pubmed">37207671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitrovi&#x107;-Ajti&#x107; O., Djiki&#x107; D., Suboti&#x10d;ki T., Bi&#x17e;i&#x107;-Radulovi&#x107; S., Beleslin-&#x10c;oki&#x107; B., Dragojevi&#x107; T., &#x17d;ivkovi&#x107; E., Miljatovi&#x107; S., &#x10c;oki&#x107; V. Sex difference in the cytokine profile among patients hospitalized for COVID-19 and during their recovery: Predominance of females in adhesion molecules and males in oxidative stress. 2022.  [(accessed on 12 March 2023)].  
Pre-print
. Available online:  https://assets.researchsquare.com/files/rs-2355363/v1/03b2c2d3-7717-473c-aedb-01abcbba5a93.pdf?c=1674560543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10610714</ArticleId><ArticleId IdType="pubmed">37896963</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong M., Yan X., Jiang Y., Jin Z., Zhu S., Zou L., Liu Y., Zheng Q., Chen G., Gui R.G., et al. Endothelial biomarkers in patients recovered from covid-19 one year after hospital discharge: A cross-sectional study. Mediterr. J. Hematol. Infect. Dis. 2022;14:e2022033. doi: 10.4084/MJHID.2022.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.4084/MJHID.2022.033</ArticleId><ArticleId IdType="pmc">PMC9084173</ArticleId><ArticleId IdType="pubmed">35615329</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller W.A. The regulation of transendothelial migration: New knowledge and new questions. Cardiovasc. Res. 2015;107:310&#x2013;320. doi: 10.1093/cvr/cvv145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvv145</ArticleId><ArticleId IdType="pmc">PMC4592322</ArticleId><ArticleId IdType="pubmed">25987544</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong M., Jiang Y., Xia D., Xiong Y., Zheng Q., Chen F., Zou L., Xiao W., Zhu Y. Elevated Expression of Serum Endothelial Cell Adhesion Molecules in COVID-19 Patients. J. Infect. Dis. 2020;222:894&#x2013;898. doi: 10.1093/infdis/jiaa349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa349</ArticleId><ArticleId IdType="pmc">PMC7337874</ArticleId><ArticleId IdType="pubmed">32582936</ArticleId></ArticleIdList></Reference><Reference><Citation>Batista F.D.M., Puga M.A.M., da Silva P.V., Oliveira R., dos Santos P.C.P., da Silva B.O., Tatara M.B., Tsuha D.H., Pires M.A.D.S., Gon&#xe7;alves C.C.M., et al. Serum biomarkers associated with SARS-CoV-2 severity. Sci. Rep. 2022;12:15999. doi: 10.1038/s41598-022-20062-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-20062-5</ArticleId><ArticleId IdType="pmc">PMC9511452</ArticleId><ArticleId IdType="pubmed">36163447</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur S., Hussain S., Kolhe K., Kumar G., Tripathi D.M., Tomar A., Kale P., Narayanan A., Bihari C., Bajpai M., et al. Elevated plasma ICAM1 levels predict 28-day mortality in cirrhotic patients with COVID-19 or bacterial sepsis. JHEP Rep. 2021;3:100303. doi: 10.1016/j.jhepr.2021.100303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhepr.2021.100303</ArticleId><ArticleId IdType="pmc">PMC8106200</ArticleId><ArticleId IdType="pubmed">33997748</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruni F., Charitos P., Lampart M., Moser S., Siegemund M., Bingisser R., Osswald S., Bassetti S., Twerenbold R., Trendelenburg M., et al. Complement and endothelial cell activation in COVID-19 patients compared to controls with suspected SARS-CoV-2 infection: A prospective cohort study. Front. Immunol. 2022;13:941742. doi: 10.3389/fimmu.2022.941742.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.941742</ArticleId><ArticleId IdType="pmc">PMC9530900</ArticleId><ArticleId IdType="pubmed">36203596</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan B.E., Wong S.W., Sum C.L.L., Lim G.H., Leung B.P., Tan C.W., Ramanathan K., Dalan R., Cheung C., Lim X.R., et al. Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: Assessing the long-term outcomes in COVID -19 patients. Am. J. Hematol. 2022;97:915&#x2013;923. doi: 10.1002/ajh.26575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26575</ArticleId><ArticleId IdType="pmc">PMC9073976</ArticleId><ArticleId IdType="pubmed">35477923</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S., DiMaio T.A., Scheef E.A., Sorenson C.M., Sheibani N. PECAM-1 regulates proangiogenic properties of endothelial cells through modulation of cell-cell and cell-matrix interactions. Am. J. Physiol. Physiol. 2010;299:C1468&#x2013;C1484. doi: 10.1152/ajpcell.00246.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00246.2010</ArticleId><ArticleId IdType="pmc">PMC3006334</ArticleId><ArticleId IdType="pubmed">20810911</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Huang M., Shen J., Wang Y., Wang R., Yuan C., Jiang L., Huang M. Serum Levels of Soluble Platelet Endothelial Cell Adhesion Molecule 1 in COVID-19 Patients Are Associated with Disease Severity. J. Infect. Dis. 2020;223:178&#x2013;179. doi: 10.1093/infdis/jiaa642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa642</ArticleId><ArticleId IdType="pmc">PMC7797759</ArticleId><ArticleId IdType="pubmed">33179035</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook-Mills J.M., Marchese M.E., Abdala-Valencia H. Vascular Cell Adhesion Molecule-1 Expression and Signaling During Disease: Regulation by Reactive Oxygen Species and Antioxidants. Antioxid. Redox Signal. 2011;15:1607&#x2013;1638. doi: 10.1089/ars.2010.3522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2010.3522</ArticleId><ArticleId IdType="pmc">PMC3151426</ArticleId><ArticleId IdType="pubmed">21050132</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborn L., Hession C., Tizard R., Vassallo C., Luhowskyj S., Chi-Rosso G., Lobb R. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell. 1989;59:1203&#x2013;1211. doi: 10.1016/0092-8674(89)90775-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(89)90775-7</ArticleId><ArticleId IdType="pubmed">2688898</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcinelli E., Petito E., Becattini C., De Robertis E., Paliani U., Sebastiano M., Vaudo G., Guglielmini G., Paciullo F., Cerotto V., et al. Role of endothelial dysfunction in the thrombotic complications of COVID-19 patients. J. Infect. 2020;82:186&#x2013;230. doi: 10.1016/j.jinf.2020.11.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.11.041</ArticleId><ArticleId IdType="pmc">PMC7708798</ArticleId><ArticleId IdType="pubmed">33275957</ArticleId></ArticleIdList></Reference><Reference><Citation>Guervilly C., Burtey S., Sabatier F., Cauchois R., Lano G., Abdili E., Daviet F., Arnaud L., Brunet P., Hraiech S., et al. Circulating Endothelial Cells as a Marker of Endothelial Injury in Severe COVID -19. J. Infect. Dis. 2020;222:1789&#x2013;1793. doi: 10.1093/infdis/jiaa528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa528</ArticleId><ArticleId IdType="pmc">PMC7454721</ArticleId><ArticleId IdType="pubmed">32812049</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao S., Luo N., Liu J., Zha H., Ai Y., Luo J., Shi S., Wu K. Elevated Serum Levels of Progranulin and Soluble Vascular Cell Adhesion Molecule-1 in Patients with COVID-19. J. Inflamm. Res. 2021;14:4785&#x2013;4794. doi: 10.2147/JIR.S330356.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S330356</ArticleId><ArticleId IdType="pmc">PMC8464378</ArticleId><ArticleId IdType="pubmed">34584437</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez S., Moreno-Casta&#xf1;o A.B., Palomo M., Martinez-Sanchez J., Torramad&#xe9;-Moix S., T&#xe9;llez A., Ventosa H., Segu&#xed; F., Escolar G., Carreras E., et al. Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes. Shock. 2021;57:95&#x2013;105. doi: 10.1097/SHK.0000000000001823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000001823</ArticleId><ArticleId IdType="pmc">PMC8662948</ArticleId><ArticleId IdType="pubmed">34172614</ArticleId></ArticleIdList></Reference><Reference><Citation>Sega F.V.D., Fortini F., Spadaro S., Ronzoni L., Zucchetti O., Manfrini M., Mikus E., Fogagnolo A., Torsani F., Pavasini R., et al. Time course of endothelial dysfunction markers and mortality in COVID-19 patients: A pilot study. Clin. Transl. Med. 2021;11:e283. doi: 10.1002/ctm2.283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.283</ArticleId><ArticleId IdType="pmc">PMC7919132</ArticleId><ArticleId IdType="pubmed">33784001</ArticleId></ArticleIdList></Reference><Reference><Citation>Gale N.W., Yancopoulos G.D. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, Angiopoietins, and ephrins in vascular development. Genes Dev. 1999;13:1055&#x2013;1066. doi: 10.1101/gad.13.9.1055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.13.9.1055</ArticleId><ArticleId IdType="pubmed">10323857</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrara N., Houck K., Jakeman L., Leung D.W. Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins. Endocr. Rev. 1992;13:18&#x2013;32. doi: 10.1210/edrv-13-1-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/edrv-13-1-18</ArticleId><ArticleId IdType="pubmed">1372863</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti- and pro-angiogenic therapies. Genes Cancer. 2011;2:1097&#x2013;1105. doi: 10.1177/1947601911423031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1947601911423031</ArticleId><ArticleId IdType="pmc">PMC3411125</ArticleId><ArticleId IdType="pubmed">22866201</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A., Jayakumar M.N., Saleh M.A., Kannan M., Halwani R., Qaisar R., Ahmad F. SARS-CoV-2 infection- induced growth factors play differential roles in COVID-19 pathogenesis. Life Sci. 2022;304:120703. doi: 10.1016/j.lfs.2022.120703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2022.120703</ArticleId><ArticleId IdType="pmc">PMC9188443</ArticleId><ArticleId IdType="pubmed">35700841</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerra-L&#xf3;pez J.A., Amezcua-Castillo L.M., Gonz&#xe1;lez-Pacheco H., Amezcua-Guerra L.M. Levels of Vascular Endothelial Growth Factor and Its Association with Pulmonary Embolism in COVID-19. J. Interf. Cytokine Res. 2022;42:444&#x2013;448. doi: 10.1089/jir.2022.0034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2022.0034</ArticleId><ArticleId IdType="pubmed">35559721</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed F., Li W., Relich R.F., Russell P.M., Zhang S., Zimmerman M.K., Yu Q. Excessive Matrix Metalloproteinase-1 and Hyperactivation of Endothelial Cells Occurred in COVID-19 Patients and Were Associated with the Severity of COVID-19. J. Infect. Dis. 2021;224:60&#x2013;69. doi: 10.1093/infdis/jiab167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab167</ArticleId><ArticleId IdType="pmc">PMC8083685</ArticleId><ArticleId IdType="pubmed">33885811</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong Y., Han J., Wu X., Zeng H., Liu J., Zhang H. VEGF-D: A novel biomarker for detection of COVID-19 progression. Crit. Care. 2020;24:373. doi: 10.1186/s13054-020-03079-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03079-y</ArticleId><ArticleId IdType="pmc">PMC7309201</ArticleId><ArticleId IdType="pubmed">32576222</ArticleId></ArticleIdList></Reference><Reference><Citation>Baskol G., &#xd6;zel M., Saracoglu H., Ulger B., Unuvar G.K., Onuk S., Bayram A., Akin A.K., Muhtaroglu S., Sagiroglu P., et al. New Avenues to Explore in SARS-CoV-2 Infection: Both TRIM25 and TRIM56 Positively Correlate with VEGF, GAS6, and sAXL in COVID-19 Patients. Viral Immunol. 2022;35:690&#x2013;699. doi: 10.1089/vim.2022.0112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2022.0112</ArticleId><ArticleId IdType="pubmed">36450108</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y. The impact of the hypoxia-VEGF-vascular permeability on COVID-19-infected patients. Exploration. 2021;1:210051. doi: 10.1002/EXP.20210051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/EXP.20210051</ArticleId><ArticleId IdType="pmc">PMC8653011</ArticleId><ArticleId IdType="pubmed">35434726</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong S.W.X., Fong S.-W., Young B.E., Chan Y.-H., Lee B., Amrun S.N., Chee R.S.-L., Yeo N.K.-W., Tambyah P., Pada S., et al. Persistent Symptoms and Association with Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients. Open Forum Infect. Dis. 2021;8:ofab156. doi: 10.1093/ofid/ofab156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab156</ArticleId><ArticleId IdType="pmc">PMC8083585</ArticleId><ArticleId IdType="pubmed">34095336</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfadda A.A., Rafiullah M., Alkhowaiter M., Alotaibi N., Alzahrani M., Binkhamis K., Siddiqui K., Youssef A., Altalhi H., Almaghlouth I., et al. Clinical and biochemical characteristics of people experiencing post-coronavirus disease 2019-related symptoms: A prospective follow-up investigation. Front. Med. 2022;9:1067082. doi: 10.3389/fmed.2022.1067082.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.1067082</ArticleId><ArticleId IdType="pmc">PMC9763306</ArticleId><ArticleId IdType="pubmed">36561720</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaskamp L., Roubal C., Uddin S., Sotzny F., Kedor C., Bauer S., Scheibenbogen C., Seifert M. Serum of Post-COVID-19 Syndrome Patients with or without ME/CFS Differentially Affects Endothelial Cell Function In Vitro. Cells. 2022;11:2376. doi: 10.3390/cells11152376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11152376</ArticleId><ArticleId IdType="pmc">PMC9367589</ArticleId><ArticleId IdType="pubmed">35954219</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbitt M., Eaton-Fitch N., Staines D., Cabanas H., Marshall-Gradisnik S. A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID) BMC Neurol. 2019;19:207. doi: 10.1186/s12883-019-1433-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-019-1433-0</ArticleId><ArticleId IdType="pmc">PMC6708220</ArticleId><ArticleId IdType="pubmed">31445522</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda T., Sun L., Tsuruoka N., Ishigaki Y., Yoshitomi Y., Yoshitake Y., Yonekura H. Hypoxia down-regulates sFlt-1 (sVEGFR-1) expression in human microvascular endothelial cells by a mechanism involving mRNA alternative processing. Biochem. J. 2011;436:399&#x2013;407. doi: 10.1042/BJ20101490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20101490</ArticleId><ArticleId IdType="pmc">PMC3133880</ArticleId><ArticleId IdType="pubmed">21382012</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasquale E.B. Eph-Ephrin Bidirectional Signaling in Physiology and Disease. Cell. 2008;133:38&#x2013;52. doi: 10.1016/j.cell.2008.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2008.03.011</ArticleId><ArticleId IdType="pubmed">18394988</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson J., Schomberg S., Schroeder W., Carpenter T.C. Endothelial EphA receptor stimulation increases lung vascular permeability. Am. J. Physiol. Cell Mol. Physiol. 2008;295:L431&#x2013;L439. doi: 10.1152/ajplung.90256.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.90256.2008</ArticleId><ArticleId IdType="pmc">PMC2536794</ArticleId><ArticleId IdType="pubmed">18599503</ArticleId></ArticleIdList></Reference><Reference><Citation>Coulthard M.G., Morgan M., Woodruff T.M., Arumugam T.V., Taylor S.M., Carpenter T.C., Lackmann M., Boyd A.W. Eph/Ephrin Signaling in Injury and Inflammation. Am. J. Pathol. 2012;181:1493&#x2013;1503. doi: 10.1016/j.ajpath.2012.06.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2012.06.043</ArticleId><ArticleId IdType="pubmed">23021982</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendoza R., Saha N., Momeni A., Gabutan E., Alawad M., Dehghani A., Diks J., Lin B., Wang D., Alshal M., et al. Ephrin-A1 and the sheddase ADAM12 are upregulated in COVID-19. Heliyon. 2021;7:e07200. doi: 10.1016/j.heliyon.2021.e07200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2021.e07200</ArticleId><ArticleId IdType="pmc">PMC8165044</ArticleId><ArticleId IdType="pubmed">34095559</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M., Facchetti F. TREM-1 (Triggering Receptor Expressed on Myeloid Cells): A New Player in Acute Inflammatory Responses. J. Infect. Dis. 2003;187:S397&#x2013;S401. doi: 10.1086/374754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/374754</ArticleId><ArticleId IdType="pubmed">12792857</ArticleId></ArticleIdList></Reference><Reference><Citation>Tammaro A., Derive M., Gibot S., Leemans J.C., Florquin S., Dessing M.C. TREM-1 and its potential ligands in non-infectious diseases: From biology to clinical perspectives. Pharmacol. Ther. 2017;177:81&#x2013;95. doi: 10.1016/j.pharmthera.2017.02.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2017.02.043</ArticleId><ArticleId IdType="pubmed">28245991</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira Y.L.M., Resende A.D.S., Martins-Filho P.R., de Moura T.R. Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: A systematic review and meta-analysis of clinical studies. Inflammopharmacology. 2022;30:1037&#x2013;1045. doi: 10.1007/s10787-022-00972-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-022-00972-6</ArticleId><ArticleId IdType="pmc">PMC8959072</ArticleId><ArticleId IdType="pubmed">35347523</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerget F., Kerget B., Y&#x131;lmaz S.I., K&#x131;z&#x131;ltun&#xe7; A. Evaluation of the relationship between TREM-1/TREM-2 ratio and clinical course in COVID-19 pneumonia. Int. J. Clin. Pract. 2021;75:e14697. doi: 10.1111/ijcp.14697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14697</ArticleId><ArticleId IdType="pmc">PMC8420347</ArticleId><ArticleId IdType="pubmed">34365706</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva-Neto P.V., de Carvalho J.C.S., Pimentel V.E., P&#xe9;rez M.M., Toro D.M., Fraga-Silva T.F.C., Fuzo C.A., Oliveira C.N.S., Rodrigues L.C., Argolo J.G.M., et al. sTREM-1 Predicts Disease Severity and Mortality in COVID-19 Patients: Involvement of Peripheral Blood Leukocytes and MMP-8 Activity. Viruses. 2021;13:2521. doi: 10.3390/v13122521.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13122521</ArticleId><ArticleId IdType="pmc">PMC8708887</ArticleId><ArticleId IdType="pubmed">34960790</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Singer M., Brahier T., Ngai M., Wright J., Weckman A.M., Erice C., Meuwly J.-Y., Hugli O., Kain K.C., Boillat-Blanco N. COVID-19 risk stratification algorithms based on sTREM-1 and IL-6 in emergency department. J. Allergy Clin. Immunol. 2020;147:99&#x2013;106.e4. doi: 10.1016/j.jaci.2020.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.10.001</ArticleId><ArticleId IdType="pmc">PMC7546666</ArticleId><ArticleId IdType="pubmed">33045281</ArticleId></ArticleIdList></Reference><Reference><Citation>de Nooijer A.H., Grondman I., Lambden S., Kooistra E.J., Janssen N.A., Kox M., Pickkers P., Joosten L.A., van de Veerdonk F.L., Derive M., et al. Increased sTREM-1 plasma concentrations are associated with poor clinical outcomes in patients with COVID-19. Biosci. Rep. 2021;41:BSR20210940. doi: 10.1042/BSR20210940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20210940</ArticleId><ArticleId IdType="pmc">PMC8298260</ArticleId><ArticleId IdType="pubmed">34195785</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotowicz K., Dixon G.L.J., Klein N.J., Peters M.J., Callard R.E. Biological function of CD40 on human endothelial cells: Costimulation with CD40 ligand and interleukin-4 selectively induces expression of vascular cell adhesion molecule-1 and P-selectin resulting in preferential adhesion of lymphocytes. Immunology. 2000;100:441&#x2013;448. doi: 10.1046/j.1365-2567.2000.00061.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2567.2000.00061.x</ArticleId><ArticleId IdType="pmc">PMC2327040</ArticleId><ArticleId IdType="pubmed">10929070</ArticleId></ArticleIdList></Reference><Reference><Citation>Mach F., Sch&#xf6;nbeck U., Sukhova G.K., Bourcier T., Bonnefoy J.-Y., Pober J.S., Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40&#x2013;CD40 ligand signaling in atherosclerosis. Proc. Natl. Acad. Sci. USA. 1997;94:1931&#x2013;1936. doi: 10.1073/pnas.94.5.1931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.5.1931</ArticleId><ArticleId IdType="pmc">PMC20020</ArticleId><ArticleId IdType="pubmed">9050882</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew M., Rahman M., Ihrman L., Erson A., Zhang S., Thorlacius H. Soluble CD40L (CD154) is increased in patients with shock. Inflamm. Res. 2010;59:979&#x2013;982. doi: 10.1007/s00011-010-0213-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-010-0213-5</ArticleId><ArticleId IdType="pubmed">20490890</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarti S., Varghese S., Vitseva O., Tanriverdi K., Freedman J.E. CD40 Ligand Influences Platelet Release of Reactive Oxygen Intermediates. Arter. Thromb. Vasc. Biol. 2005;25:2428&#x2013;2434. doi: 10.1161/01.ATV.0000184765.59207.f3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.0000184765.59207.f3</ArticleId><ArticleId IdType="pubmed">16141403</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen L.J.H., Petersen J.E.V., Eugen-Olsen J. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation. Front. Immunol. 2021;12:780641. doi: 10.3389/fimmu.2021.780641.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.780641</ArticleId><ArticleId IdType="pmc">PMC8674945</ArticleId><ArticleId IdType="pubmed">34925360</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovina N., Akinosoglou K., Eugen-Olsen J., Hayek S., Reiser J., Giamarellos-Bourboulis E.J. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit. Care. 2020;24:187. doi: 10.1186/s13054-020-02897-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-02897-4</ArticleId><ArticleId IdType="pmc">PMC7191969</ArticleId><ArticleId IdType="pubmed">32354367</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang M., Li L., Shen J., Wang Y., Wang R., Yuan C., Huang M., Jiang L. Plasma levels of the active form of suPAR are associated with COVID-19 severity. Crit. Care. 2020;24:704. doi: 10.1186/s13054-020-03336-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03336-0</ArticleId><ArticleId IdType="pmc">PMC7770382</ArticleId><ArticleId IdType="pubmed">33372603</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias A., Mouzarou A., Samara E., Xanthos T., Ischaki E., Pantazopoulos I. Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients. Mol. Diagn. Ther. 2020;24:517&#x2013;521. doi: 10.1007/s40291-020-00481-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40291-020-00481-8</ArticleId><ArticleId IdType="pmc">PMC7327460</ArticleId><ArticleId IdType="pubmed">32613288</ArticleId></ArticleIdList></Reference><Reference><Citation>Enocsson H., Idoff C., Gustafsson A., Govender M., Hopkins F., Larsson M., Nilsdotter-Augustinsson &#xc5;., Sj&#xf6;wall J. Soluble Urokinase Plasminogen Activator Receptor (suPAR) Independently Predicts Severity and Length of Hospitalisation in Patients with COVID-19. Front. Med. 2021;8:791716. doi: 10.3389/fmed.2021.791716.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.791716</ArticleId><ArticleId IdType="pmc">PMC8674575</ArticleId><ArticleId IdType="pubmed">34926532</ArticleId></ArticleIdList></Reference><Reference><Citation>Oulhaj A., Alsuwaidi A.R., Suliman A., Gasmelseed H., Khan S., Alawi S., Hukan Y., George J., Alshamsi F., Sheikh F., et al. Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study. Int. J. Infect. Dis. 2021;107:188&#x2013;194. doi: 10.1016/j.ijid.2021.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.04.026</ArticleId><ArticleId IdType="pmc">PMC8056823</ArticleId><ArticleId IdType="pubmed">33862208</ArticleId></ArticleIdList></Reference><Reference><Citation>Velissaris D., Dimopoulos G., Parissis J., Alexiou Z., Antonakos N., Babalis D., Gerakari S., Kaldis V., Koutoukas P., Lada M., et al. Prognostic Role of Soluble Urokinase Plasminogen Activator Receptor at the Emergency Department: A Position Paper by the Hellenic Sepsis Study Group. Infect. Dis. Ther. 2020;9:407&#x2013;416. doi: 10.1007/s40121-020-00301-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-020-00301-w</ArticleId><ArticleId IdType="pmc">PMC7217599</ArticleId><ArticleId IdType="pubmed">32399855</ArticleId></ArticleIdList></Reference><Reference><Citation>Velissaris D., Lagadinou M., Paraskevas T., Oikonomou E., Karamouzos V., Karteri S., Bousis D., Pantzaris N., Tsiotsios K., Marangos M. Evaluation of Plasma Soluble Urokinase Plasminogen Activator Receptor Levels in Patients with COVID-19 and Non-COVID-19 Pneumonia: An Observational Cohort Study. J. Clin. Med. Res. 2021;13:474&#x2013;478. doi: 10.14740/jocmr4579.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/jocmr4579</ArticleId><ArticleId IdType="pmc">PMC8510652</ArticleId><ArticleId IdType="pubmed">34691321</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold D.T., Attwood M., Barratt S., Morley A., Elvers K.T., McKernon J., Donald C., Oates A., Noel A., MacGowan A., et al. Predicting outcomes of COVID-19 from admission biomarkers: A prospective UK cohort study. Emerg. Med. J. 2021;38:543&#x2013;548. doi: 10.1136/emermed-2020-210380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/emermed-2020-210380</ArticleId><ArticleId IdType="pubmed">34021028</ArticleId></ArticleIdList></Reference><Reference><Citation>Napolitano F., Di Spigna G., Vargas M., Iacovazzo C., Pinchera B., Cernia D.S., Ricciardone M., Covelli B., Servillo G., Gentile I., et al. Soluble Urokinase Receptor as a Promising Marker for Early Prediction of Outcome in COVID-19 Hospitalized Patients. J. Clin. Med. 2021;10:4914. doi: 10.3390/jcm10214914.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10214914</ArticleId><ArticleId IdType="pmc">PMC8584815</ArticleId><ArticleId IdType="pubmed">34768433</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright S.D., Ramos R.A., Tobias P.S., Ulevitch R.J., Mathison J.C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990;249:1431&#x2013;1433. doi: 10.1126/science.1698311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1698311</ArticleId><ArticleId IdType="pubmed">1698311</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey E.A., Finlay B.B. Lipopolysaccharide induces apoptosis in a bovine endothelial cell line via a soluble CD14 dependent pathway. Microb. Pathog. 1998;24:101&#x2013;109. doi: 10.1006/mpat.1997.0178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/mpat.1997.0178</ArticleId><ArticleId IdType="pubmed">9480792</ArticleId></ArticleIdList></Reference><Reference><Citation>Mussap M., Noto A., Fravega M., Fanos V. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: New clinical and analytical perspectives for two old biomarkers. J. Matern. Neonatal Med. 2011;24:12&#x2013;14. doi: 10.3109/14767058.2011.601923.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/14767058.2011.601923</ArticleId><ArticleId IdType="pubmed">21740312</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukada A., Kitagawa Y., Matsuoka M., Sakai J., Imai K., Tarumoto N., Orihara Y., Kawamura R., Takeuchi S., Maesaki S., et al. Presepsin as a predictive biomarker of severity in COVID-19: A case series. J. Med. Virol. 2020;93:99&#x2013;101. doi: 10.1002/jmv.26164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26164</ArticleId><ArticleId IdType="pmc">PMC7307131</ArticleId><ArticleId IdType="pubmed">32530491</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaninotto M., Mion M.M., Cosma C., Rinaldi D., Plebani M. Presepsin in risk stratification of SARS-CoV-2 patients. Clin. Chim. Acta. 2020;507:161&#x2013;163. doi: 10.1016/j.cca.2020.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.04.020</ArticleId><ArticleId IdType="pmc">PMC7175898</ArticleId><ArticleId IdType="pubmed">32333860</ArticleId></ArticleIdList></Reference><Reference><Citation>Karacaer C., Sert H., Demirci T., Var&#x131;m C., Kaya G., Genc A.B., Ergenc D.C.H., Ergenc Z., Yaylac&#x131; S., Nalbant A., et al. The significance of a novel inflammatory biomarker, presepsin, in predicting disease prognosis in patients with COVID-19. Eur. Rev. Med. Pharmacol. Sci. 2022;26:8612&#x2013;8619. doi: 10.26355/eurrev_202211_30398.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202211_30398</ArticleId><ArticleId IdType="pubmed">36459042</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukui S., Ikeda K., Kobayashi M., Nishida K., Yamada K., Horie S., Shimada Y., Miki H., Goto H., Hayashi K., et al. Predictive prognostic biomarkers in patients with COVID-19 infection. Mol. Med. Rep. 2022;27:15. doi: 10.3892/mmr.2022.12902.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2022.12902</ArticleId><ArticleId IdType="pubmed">36453231</ArticleId></ArticleIdList></Reference><Reference><Citation>Arakawa N., Matsuyama S., Matsuoka M., Kitamura I., Miyashita K., Kitagawa Y., Imai K., Ogawa K., Maeda T., Saito Y., et al. Serum stratifin and presepsin as candidate biomarkers for early detection of COVID-19 disease progression. J. Pharmacol. Sci. 2022;150:21&#x2013;30. doi: 10.1016/j.jphs.2022.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jphs.2022.06.002</ArticleId><ArticleId IdType="pmc">PMC9188980</ArticleId><ArticleId IdType="pubmed">35926945</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.W.M., Lee H.M., Lee S.H.M., Jo S.J., Lee J.M., Lim J.M. Usefulness of monocyte distribution width and presepsin for early assessment of disease severity in COVID-19 patients. Medicine. 2022;101:e29592. doi: 10.1097/MD.0000000000029592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000029592</ArticleId><ArticleId IdType="pmc">PMC9258971</ArticleId><ArticleId IdType="pubmed">35801752</ArticleId></ArticleIdList></Reference><Reference><Citation>Assal H.H., Abdelrahman S.M., Abdelbasset M.A., Abdelaziz M., Sabry I.M., Shaban M.M. Presepsin as a Novel Biomarker in predicting In-hospital Mortality in Patients with COVID-19 Pneumonia. Int. J. Infect. Dis. 2022;118:155&#x2013;163. doi: 10.1016/j.ijid.2022.02.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.02.054</ArticleId><ArticleId IdType="pmc">PMC8893933</ArticleId><ArticleId IdType="pubmed">35248717</ArticleId></ArticleIdList></Reference><Reference><Citation>Won T., Wood M.K., Hughes D.M., Talor M.V., Ma Z., Schneider J., Skinner J.T., Asady B., Goerlich E., Halushka M.K., et al. Endothelial thrombomodulin downregulation caused by hypoxia contributes to severe infiltration and coagulopathy in COVID-19 patient lungs. EBioMedicine. 2022;75:103812. doi: 10.1016/j.ebiom.2022.103812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103812</ArticleId><ArticleId IdType="pmc">PMC8756077</ArticleId><ArticleId IdType="pubmed">35033854</ArticleId></ArticleIdList></Reference><Reference><Citation>Mast A.E., Wolberg A.S., Gailani D., Garvin M.R., Alvarez C., Miller J.I., Aronow B., Jacobson D. SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung. Elife. 2021;10:e64330. doi: 10.7554/eLife.64330.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.64330</ArticleId><ArticleId IdType="pmc">PMC8049742</ArticleId><ArticleId IdType="pubmed">33683204</ArticleId></ArticleIdList></Reference><Reference><Citation>Pires B.G., Calado R.T. Hyper-inflammation and complement in COVID -19. Am. J. Hematol. 2023;98:S74&#x2013;S81. doi: 10.1002/ajh.26746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26746</ArticleId><ArticleId IdType="pubmed">36999459</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayyadi M., Hassani S., Shams M., Dorgalaleh A. Status of major hemostatic components in the setting of COVID-19: The effect on endothelium, platelets, coagulation factors, fibrinolytic system, and complement. Ann. Hematol. 2023:1&#x2013;16. doi: 10.1007/s00277-023-05234-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-023-05234-1</ArticleId><ArticleId IdType="pmc">PMC10115391</ArticleId><ArticleId IdType="pubmed">37074380</ArticleId></ArticleIdList></Reference><Reference><Citation>Magro C., Mulvey J.J., Berlin D., Nuovo G., Salvatore S., Harp J., Baxter-Stoltzfus A., Laurence J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl. Res. 2020;220:1&#x2013;13. doi: 10.1016/j.trsl.2020.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2020.04.007</ArticleId><ArticleId IdType="pmc">PMC7158248</ArticleId><ArticleId IdType="pubmed">32299776</ArticleId></ArticleIdList></Reference><Reference><Citation>de Nooijer A.H., Grondman I., Janssen N.A.F., Netea M.G., Willems L., van de Veerdonk F.L., Giamarellos-Bourboulis E.J., Toonen E.J.M., Joosten L.A.B., Jaeger M., et al. Complement Activation in the Disease Course of Coronavirus Disease 2019 and Its Effects on Clinical Outcomes. J. Infect. Dis. 2020;223:214&#x2013;224. doi: 10.1093/infdis/jiaa646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa646</ArticleId><ArticleId IdType="pmc">PMC7797765</ArticleId><ArticleId IdType="pubmed">33038254</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmudpour M., Roozbeh J., Keshavarz M., Farrokhi S., Nabipour I. COVID-19 cytokine storm: The anger of inflammation. Cytokine. 2020;133:155151. doi: 10.1016/j.cyto.2020.155151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2020.155151</ArticleId><ArticleId IdType="pmc">PMC7260598</ArticleId><ArticleId IdType="pubmed">32544563</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruggeri Z.M. The role of von Willebrand factor in thrombus formation. Thromb. Res. 2007;120:S5&#x2013;S9. doi: 10.1016/j.thromres.2007.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2007.03.011</ArticleId><ArticleId IdType="pmc">PMC2702526</ArticleId><ArticleId IdType="pubmed">17493665</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladikou E.E., Sivaloganathan H., Milne K.M., Arter W.E., Ramasamy R., Saad R., Stoneham S.M., Philips B., Eziefula A.C., Chevassut T. Von Willebrand factor (vWF): Marker of endothelial damage and thrombotic risk in COVID-19? Clin. Med. 2020;20:e178&#x2013;e182. doi: 10.7861/clinmed.2020-0346.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020-0346</ArticleId><ArticleId IdType="pmc">PMC7539718</ArticleId><ArticleId IdType="pubmed">32694169</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch A., Labreuche J., Lassalle F., Goutay J., Caplan M., Charbonnier L., Rohn A., Jeanpierre E., Dupont A., Duhamel A., et al. Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID-19. J. Thromb. Haemost. 2020;18:2942&#x2013;2953. doi: 10.1111/jth.15067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15067</ArticleId><ArticleId IdType="pmc">PMC7461161</ArticleId><ArticleId IdType="pubmed">32881304</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Sullivan J.M., Mc Gonagle D., Ward S.E., Preston R.J.S., O'Donnell J.S. Endothelial cells orchestrate COVID-19 coagulopathy. Lancet Haematol. 2020;7:e553&#x2013;e555. doi: 10.1016/S2352-3026(20)30215-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(20)30215-5</ArticleId><ArticleId IdType="pmc">PMC7326442</ArticleId><ArticleId IdType="pubmed">32619412</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetti M., Gomez-Rosas P., Sanga E., Gamba S., Verzeroli C., Russo L., Restuccia F., Schieppati F., Bonanomi E., Rizzi M., et al. Endothelium Activation Markers in Severe Hospitalized COVID-19 Patients: Role in Mortality Risk Prediction. TH Open. 2021;05:e253&#x2013;e263. doi: 10.1055/s-0041-1731711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1731711</ArticleId><ArticleId IdType="pmc">PMC8255108</ArticleId><ArticleId IdType="pubmed">34235394</ArticleId></ArticleIdList></Reference><Reference><Citation>Busch M.H., Timmermans S.A., Van Kuijk S.M., Aendekerk J.P., Ysermans R., Van Doorn D.P., Potjewijd J., Van de Poll M.C., Van der Horst I.C., Damoiseaux J.G., et al. Thrombin formation via the intrinsic coagulation pathway and von Willebrand factor reflect disease severity in COVID-19. Haematologica. 2022;108:1417&#x2013;1422. doi: 10.3324/haematol.2022.281693.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2022.281693</ArticleId><ArticleId IdType="pmc">PMC10153543</ArticleId><ArticleId IdType="pubmed">36519327</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera-Garcia D., Miltiades A., Yim P., Parsons S., Elisman K., Mansouri M.T., Wagener G., Harrison N.L. Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients. Int. J. Hematol. 2022;116:937&#x2013;946. doi: 10.1007/s12185-022-03437-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-022-03437-2</ArticleId><ArticleId IdType="pmc">PMC9395834</ArticleId><ArticleId IdType="pubmed">35994163</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanini L., Ruberto F., Curreli M., Chistolini A., Schiera E., Marrapodi R., Visentini M., Ceccarelli G., D'Ettorre G., Santoro C., et al. Increased von Willebrand Factor Platelet-Binding Capacity Is Related to Poor Prognosis in COVID-19 Patients. Thromb. Haemost. 2022;123:118&#x2013;122. doi: 10.1055/a-1962-5447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1962-5447</ArticleId><ArticleId IdType="pmc">PMC9831687</ArticleId><ArticleId IdType="pubmed">36252812</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray M., Guzel M.A., Lam F., Yee A., Cruz M.A., Rumbaut R.E. High levels of von Willebrand factor with reduced specific activities in hospitalized patients with or without COVID-19. J. Thromb. Thrombolysis. 2022;54:211&#x2013;216. doi: 10.1007/s11239-022-02679-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-022-02679-5</ArticleId><ArticleId IdType="pmc">PMC9314532</ArticleId><ArticleId IdType="pubmed">35881214</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Wu Q., Qin Z., Hou X., Zhang L., Guo J., Li Y., Yang F., Zhang Y., Wu Q., et al. Serum levels of laminin and von Willebrand factor in COVID-19 survivors 6 months after discharge. Int. J. Infect. Dis. 2021;115:134&#x2013;141. doi: 10.1016/j.ijid.2021.11.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.11.032</ArticleId><ArticleId IdType="pmc">PMC8626146</ArticleId><ArticleId IdType="pubmed">34843955</ArticleId></ArticleIdList></Reference><Reference><Citation>Fremont R.D., Koyama T., Calfee C.S., Wu W., Dossett L.A., Bossert F.R., Mitchell D., Wickersham N., Bernard G.R., Matthay M.A., et al. Acute Lung Injury in Patients with Traumatic Injuries: Utility of a Panel of Biomarkers for Diagnosis and Pathogenesis. J. Trauma Inj. Infect. Crit. Care. 2010;68:1121&#x2013;1127. doi: 10.1097/TA.0b013e3181c40728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3181c40728</ArticleId><ArticleId IdType="pmc">PMC3347639</ArticleId><ArticleId IdType="pubmed">20038857</ArticleId></ArticleIdList></Reference><Reference><Citation>Joly B.S., Darmon M., Dekimpe C., Dupont T., Dumas G., Yvin E., Beranger N., Vanhoorelbeke K., Azoulay E., Veyradier A. Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVID-19 patients. J. Thromb. Haemost. 2021;19:2193&#x2013;2198. doi: 10.1111/jth.15445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15445</ArticleId><ArticleId IdType="pmc">PMC8420340</ArticleId><ArticleId IdType="pubmed">34219357</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazzan M., Montaruli B., Sciascia S., Cosseddu D., Norbiato C., Roccatello D. Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients. Intern. Emerg. Med. 2020;15:861&#x2013;863. doi: 10.1007/s11739-020-02394-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-020-02394-0</ArticleId><ArticleId IdType="pmc">PMC7300200</ArticleId><ArticleId IdType="pubmed">32557383</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasi A., von Meijenfeldt F.A., Adelmeijer J., Calvo A., Iba&#xf1;ez C., Perdomo J., Reverter J.C., Lisman T. In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation. J. Thromb. Haemost. 2020;18:2646&#x2013;2653. doi: 10.1111/jth.15043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15043</ArticleId><ArticleId IdType="pmc">PMC7436627</ArticleId><ArticleId IdType="pubmed">32762118</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman A., Beun R., Sikma M., Westerink J., Kusadasi N. Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS-CoV-2. Int. J. Lab. Hematol. 2020;42:13244. doi: 10.1111/ijlh.13244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijlh.13244</ArticleId><ArticleId IdType="pmc">PMC7280565</ArticleId><ArticleId IdType="pubmed">32441844</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;n-Rojas R.M., Chasco-Ganuza M., Casanova-Prieto S., Delgado-Pinos V.E., P&#xe9;rez-Rus G., Duque-Gonz&#xe1;lez P., Sancho M., D&#xed;ez-Mart&#xed;n J.L., Pascual-Izquierdo C. A mild deficiency of ADAMTS13 is associated with severity in COVID-19: Comparison of the coagulation profile in critically and noncritically ill patients: An international journal in haemostasis and thrombosis. Blood Coagul. Fibrinolysis. 2021;32:458&#x2013;467. doi: 10.1097/MBC.0000000000001068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MBC.0000000000001068</ArticleId><ArticleId IdType="pmc">PMC8527912</ArticleId><ArticleId IdType="pubmed">34310402</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolgushina N., Gorodnova E., Beznoshenco O., Romanov A., Menzhinskaya I., Krechetova L., Sukhikh G. Von Willebrand Factor and ADAMTS-13 Are Associated with the Severity of COVID-19 Disease. J. Clin. Med. 2022;11:4006. doi: 10.3390/jcm11144006.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11144006</ArticleId><ArticleId IdType="pmc">PMC9317441</ArticleId><ArticleId IdType="pubmed">35887770</ArticleId></ArticleIdList></Reference><Reference><Citation>Morici N., Bottiroli M., Fumagalli R., Marini C., Cattaneo M. Role of von Willebrand Factor and ADAMTS-13 in the Pathogenesis of Thrombi in SARS-CoV-2 Infection: Time to Rethink. Thromb. Haemost. 2020;120:1339&#x2013;1342. doi: 10.1055/s-0040-1713400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1713400</ArticleId><ArticleId IdType="pubmed">32575136</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasannan N., Heightman M., Hillman T., Wall E., Bell R., Kessler A., Neave L., Doyle A.J., Devaraj A., Singh D., et al. Impaired exercise capacity in post&#x2013;COVID-19 syndrome: The role of VWF-ADAMTS13 axis. Blood Adv. 2022;6:4041&#x2013;4048. doi: 10.1182/bloodadvances.2021006944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021006944</ArticleId><ArticleId IdType="pmc">PMC9098525</ArticleId><ArticleId IdType="pubmed">35543533</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackman N., Tilley R.E., Key N.S. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler. Thromb. Vasc. Biol. 2007;27:1687&#x2013;1693. doi: 10.1161/ATVBAHA.107.141911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.107.141911</ArticleId><ArticleId IdType="pubmed">17556654</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing H., Wu X., Xiang M., Liu L., Novakovic V.A., Shi J. Pathophysiological mechanisms of thrombosis in acute and long COVID-19. Front. Immunol. 2022;13:992384. doi: 10.3389/fimmu.2022.992384.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.992384</ArticleId><ArticleId IdType="pmc">PMC9709252</ArticleId><ArticleId IdType="pubmed">36466841</ArticleId></ArticleIdList></Reference><Reference><Citation>Subrahmanian S., Borczuk A., Salvatore S., Fung K., Merrill J.T., Laurence J., Ahamed J. Tissue factor upregulation is associated with SARS-CoV-2 in the lungs of COVID-19 patients. J. Thromb. Haemost. 2021;19:2268&#x2013;2274. doi: 10.1111/jth.15451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15451</ArticleId><ArticleId IdType="pmc">PMC8565501</ArticleId><ArticleId IdType="pubmed">34236752</ArticleId></ArticleIdList></Reference><Reference><Citation>Francischetti I.M., Toomer K., Zhang Y., Jani J., Siddiqui Z., Brotman D.J., Hooper J.E., Kickler T.S. Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection. eClinicalMedicine. 2021;39:101069. doi: 10.1016/j.eclinm.2021.101069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101069</ArticleId><ArticleId IdType="pmc">PMC8342934</ArticleId><ArticleId IdType="pubmed">34377969</ArticleId></ArticleIdList></Reference><Reference><Citation>Bautista-Vargas M., Bonilla-Abad&#xed;a F., Ca&#xf1;as C.A. Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID-19. J. Thromb. Thrombolysis. 2020;50:479&#x2013;483. doi: 10.1007/s11239-020-02172-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02172-x</ArticleId><ArticleId IdType="pmc">PMC7282470</ArticleId><ArticleId IdType="pubmed">32519164</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackman N., Antoniak S., Wolberg A.S., Kasthuri R., Key N.S. Coagulation Abnormalities and Thrombosis in Patients Infected with SARS-CoV-2 and Other Pandemic Viruses. Arter. Thromb. Vasc. Biol. 2020;40:2033&#x2013;2044. doi: 10.1161/ATVBAHA.120.314514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.120.314514</ArticleId><ArticleId IdType="pmc">PMC7447001</ArticleId><ArticleId IdType="pubmed">32657623</ArticleId></ArticleIdList></Reference><Reference><Citation>Ca&#xf1;as C.A., Ca&#xf1;as F., Bautista-Vargas M., Bonilla-Abad&#xed;a F. Role of Tissue Factor in the Pathogenesis of COVID-19 and the Possible Ways to Inhibit It. Clin. Appl. Thromb. Hemost. Off. J. Int. Acad. Clin. Appl. Thromb. Hemost. 2021;27:10760296211003983. doi: 10.1177/10760296211003983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/10760296211003983</ArticleId><ArticleId IdType="pmc">PMC8020089</ArticleId><ArticleId IdType="pubmed">33784877</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackman N., Sachettor A.T.A. Tissue factor and COVID-19: An update. Curr. Drug Targets. 2022;23:1573&#x2013;1577. doi: 10.2174/1389450123666220926144432.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389450123666220926144432</ArticleId><ArticleId IdType="pubmed">36165519</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramaniam S., Kothari H., Bosmann M. Tissue factor in COVID-19-associated coagulopathy. Thromb. Res. 2022;220:35&#x2013;47. doi: 10.1016/j.thromres.2022.09.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2022.09.025</ArticleId><ArticleId IdType="pmc">PMC9525243</ArticleId><ArticleId IdType="pubmed">36265412</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaie A. Regulation of the protein C anticoagulant and antiinflammatory pathways. Curr. Med. Chem. 2010;17:2059&#x2013;2069. doi: 10.2174/092986710791233706.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/092986710791233706</ArticleId><ArticleId IdType="pmc">PMC2904412</ArticleId><ArticleId IdType="pubmed">20423310</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina P., Navarro S., Estell&#xe9;s A., Vay&#xe1; A., Woodhams B., Mira Y., Villa P., Migaud-Fressart M., Ferrando F., Aznar J., et al. Contribution of polymorphisms in the endothelial protein C receptor gene to soluble endothelial protein C receptor and circulating activated protein C levels, and thrombotic risk. Thromb. Haemost. 2004;91:905&#x2013;911. doi: 10.1160/TH03-10-0657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH03-10-0657</ArticleId><ArticleId IdType="pubmed">15116250</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro S., Medina P., Mira Y., Estelles A., Villa P., Ferrando F., Vaya A., Bertina R.M., Espa&#xf1;a F. Haplotypes of the EPCR gene, prothrombin levels, and the risk of venous thrombosis in carriers of the prothrombin G20210A mutation. Haematologica. 2008;93:885&#x2013;891. doi: 10.3324/haematol.12448.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.12448</ArticleId><ArticleId IdType="pubmed">18403391</ArticleId></ArticleIdList></Reference><Reference><Citation>Saposnik B., Reny J.-L., Gaussem P., Emmerich J., Aiach M., Gandrille S. A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. Blood. 2004;103:1311&#x2013;1318. doi: 10.1182/blood-2003-07-2520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2003-07-2520</ArticleId><ArticleId IdType="pubmed">14576048</ArticleId></ArticleIdList></Reference><Reference><Citation>Simioni P., Morboeuf O., Tognin G., Gavasso S., Tormene D., Woodhams B., Pagnan A. Soluble endothelial protein C receptor (sEPCR) levels and venous thromboembolism in carriers of two dysfunctional protein C variants. Thromb. Res. 2006;117:523&#x2013;528. doi: 10.1016/j.thromres.2005.04.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2005.04.029</ArticleId><ArticleId IdType="pubmed">15921724</ArticleId></ArticleIdList></Reference><Reference><Citation>De Willige S.U., Van Marion V., Rosendaal F.R., Vos H.L., De Visser M.C.H., Bertina R.M. Haplotypes of the EPCR gene, plasma sEPCR levels and the risk of deep venous thrombosis. J. Thromb. Haemost. 2004;2:1305&#x2013;1310. doi: 10.1046/j.1538-7836.2004.00855.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1538-7836.2004.00855.x</ArticleId><ArticleId IdType="pubmed">15304035</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassiliou A.G., Keskinidou C., Jahaj E., Gallos P., Zacharis A., Athanasiou N., Tsipilis S., Mastora Z., Dimopoulou I., Kotanidou A., et al. Could Soluble Endothelial Protein C Receptor Levels Recognize Sars-Cov2-Positive Patients Requiring Hospitalization? Shock. 2021;56:733&#x2013;736. doi: 10.1097/SHK.0000000000001780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000001780</ArticleId><ArticleId IdType="pmc">PMC8518207</ArticleId><ArticleId IdType="pubmed">33756504</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourin M.C. [Thrombomodulin: A new proteoglycan. Structure-function relation] Ann. Biol. Clin. 1991;49:199&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">1656816</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;hlin A., Larsson K., Hansson M. Soluble thrombomodulin activity and soluble thrombomodulin antigen in plasma. J. Thromb. Haemost. 2005;3:976&#x2013;982. doi: 10.1111/j.1538-7836.2005.01267.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2005.01267.x</ArticleId><ArticleId IdType="pubmed">15869594</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhainaut J.-F., Yan S.B., Cariou A., Mira J.-P. Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis. Crit. Care Med. 2002;30:S318&#x2013;S324. doi: 10.1097/00003246-200205001-00023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200205001-00023</ArticleId><ArticleId IdType="pubmed">12004254</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouck E.G., Denorme F., Holle L.A., Middelton E.A., Blair A., De Laat B., Schiffman J.D., Yost C.C., Rondina M.T., Wolberg A.S., et al. COVID-19 and Sepsis Are Associated with Different Abnormalities in Plasma Procoagulant and Fibrinolytic Activity. Arter. Thromb. Vasc. Biol. 2020;41:401&#x2013;414. doi: 10.1161/ATVBAHA.120.315338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.120.315338</ArticleId><ArticleId IdType="pmc">PMC7942774</ArticleId><ArticleId IdType="pubmed">33196292</ArticleId></ArticleIdList></Reference><Reference><Citation>Juneja G.K., Castelo M., Yeh C.H., Cerroni S.E., Hansen B.E., Chessum J.E., Abraham J., Cani E., Dwivedi D.J., Fraser D.D., et al. Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID-19: A single-center prospective longitudinal study. J. Thromb. Haemost. 2021;19:1546&#x2013;1557. doi: 10.1111/jth.15327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15327</ArticleId><ArticleId IdType="pmc">PMC8250276</ArticleId><ArticleId IdType="pubmed">33826233</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H., Townsend L., Morrin H., Ahmad A., Comerford C., Karampini E., Englert H., Byrne M., Bergin C., O&#x2019;sullivan J.M., et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J. Thromb. Haemost. 2021;19:2546&#x2013;2553. doi: 10.1111/jth.15490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15490</ArticleId><ArticleId IdType="pmc">PMC8420256</ArticleId><ArticleId IdType="pubmed">34375505</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilos M., Petousis S., Parthenakis F. Interaction between platelets and endothelium: From pathophysiology to new therapeutic options. Cardiovasc. Diagn. Ther. 2018;8:568&#x2013;580. doi: 10.21037/cdt.2018.07.01.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/cdt.2018.07.01</ArticleId><ArticleId IdType="pmc">PMC6232347</ArticleId><ArticleId IdType="pubmed">30498682</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer-Acosta Y., Gonz&#xe1;lez M., Fernandez M.T., Valance W.A. Emerging Roles for Platelets in Inflammation and Disease. J. Infect. Dis. Ther. 2014;2:149. doi: 10.4172/2332-0877.1000149.</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2332-0877.1000149</ArticleId><ArticleId IdType="pmc">PMC5531291</ArticleId><ArticleId IdType="pubmed">28758142</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam F.W., Vijayan K.V., Rumbaut R.E. Platelets and Their Interactions with Other Immune Cells. Compr. Physiol. 2015;5:1265&#x2013;1280. doi: 10.1002/cphy.c140074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cphy.c140074</ArticleId><ArticleId IdType="pmc">PMC4510953</ArticleId><ArticleId IdType="pubmed">26140718</ArticleId></ArticleIdList></Reference><Reference><Citation>Kral J.B., Schrottmaier W.C., Salzmann M., Assinger A. Platelet interaction with innate immune cells. Transfus. Med. Hemotherapy Off. Organ Dtsch. Ges. Transfus. Immunhamatol. 2016;43:78&#x2013;88. doi: 10.1159/000444807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000444807</ArticleId><ArticleId IdType="pmc">PMC4872052</ArticleId><ArticleId IdType="pubmed">27226790</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett T.J., Cornwell M., Myndzar K., Rolling C.C., Xia Y., Drenkova K., Biebuyck A., Fields A.T., Tawil M., Luttrell-Williams E., et al. Platelets amplify endotheliopathy in COVID-19. Sci. Adv. 2021;7:eabh2434. doi: 10.1126/sciadv.abh2434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abh2434</ArticleId><ArticleId IdType="pmc">PMC8442885</ArticleId><ArticleId IdType="pubmed">34516880</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossouw T.M., Anderson R., Manga P., Feldman C. Emerging Role of Platelet-Endothelium Interactions in the Pathogenesis of Severe SARS-CoV-2 Infection-Associated Myocardial Injury. Front. Immunol. 2022;13:776861. doi: 10.3389/fimmu.2022.776861.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.776861</ArticleId><ArticleId IdType="pmc">PMC8854752</ArticleId><ArticleId IdType="pubmed">35185878</ArticleId></ArticleIdList></Reference><Reference><Citation>Hottz E.D., Bozza P.T. Platelet-leukocyte interactions in COVID-19: Contributions to hypercoagulability, inflammation, and disease severity. Res. Pract. Thromb. Haemost. 2022;6:e12709. doi: 10.1002/rth2.12709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12709</ArticleId><ArticleId IdType="pmc">PMC9058941</ArticleId><ArticleId IdType="pubmed">35509326</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H., Xu L., Yu S., Hong W., Huang M., Xu P. Therapeutics targeting the fibrinolytic system. Exp. Mol. Med. 2020;52:367&#x2013;379. doi: 10.1038/s12276-020-0397-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-020-0397-x</ArticleId><ArticleId IdType="pmc">PMC7156416</ArticleId><ArticleId IdType="pubmed">32152451</ArticleId></ArticleIdList></Reference><Reference><Citation>Norooznezhad A.H., Mansouri K. Endothelial cell dysfunction, coagulation, and angiogenesis in coronavirus disease 2019 (COVID-19) Microvasc. Res. 2021;137:104188. doi: 10.1016/j.mvr.2021.104188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mvr.2021.104188</ArticleId><ArticleId IdType="pmc">PMC8135191</ArticleId><ArticleId IdType="pubmed">34022205</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Farabi M.J., Nugraha R.A., Marsudi B.A., Azmi Y. Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis. Microvasc. Res. 2021;138:104224. doi: 10.1016/j.mvr.2021.104224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mvr.2021.104224</ArticleId><ArticleId IdType="pmc">PMC8279939</ArticleId><ArticleId IdType="pubmed">34273359</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji H.-L., Zhao R., Matalon S., Matthay M.A., Romagnoli S., Peris A., De Gaudio A.R., Geppetti P., Ogawa H., Asakura H., et al. Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility. Physiol. Rev. 2020;100:1065&#x2013;1075. doi: 10.1152/physrev.00013.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00013.2020</ArticleId><ArticleId IdType="pmc">PMC7191627</ArticleId><ArticleId IdType="pubmed">32216698</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry B.M., Benoit S.W., Hoehn J., Lippi G., Favaloro E.J., Benoit J.L. Circulating Plasminogen Concentration at Admission in Patients with Coronavirus Disease 2019 (COVID-19) Semin. Thromb. Hemost. 2020;46:859&#x2013;862. doi: 10.1055/s-0040-1715454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1715454</ArticleId><ArticleId IdType="pmc">PMC7645831</ArticleId><ArticleId IdType="pubmed">32882718</ArticleId></ArticleIdList></Reference><Reference><Citation>Cesari M., Pahor M., Incalzi R.A. REVIEW: Plasminogen Activator Inhibitor-1 (PAI-1): A Key Factor Linking Fibrinolysis and Age-Related Subclinical and Clinical Conditions. Cardiovasc. Ther. 2010;28:e72&#x2013;e91. doi: 10.1111/j.1755-5922.2010.00171.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1755-5922.2010.00171.x</ArticleId><ArticleId IdType="pmc">PMC2958211</ArticleId><ArticleId IdType="pubmed">20626406</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry B.M., Cheruiyot I., Benoit J.L., Lippi G., Proh&#xe1;szka Z., Favaloro E.J., Benoit S.W. Circulating Levels of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 Are Independent Predictors of Coronavirus Disease 2019 Severity: A Prospective, Observational Study. Semin. Thromb. Hemost. 2021;47:451&#x2013;455. doi: 10.1055/s-0040-1722308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1722308</ArticleId><ArticleId IdType="pubmed">33482678</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y., Warnock M., Harbaugh A., Yalavarthi S., Gockman K., Zuo M., Madison J.A., Knight J.S., Kanthi Y., Lawrence D.A. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Sci. Rep. 2021;11:1580. doi: 10.1038/s41598-020-80010-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-80010-z</ArticleId><ArticleId IdType="pmc">PMC7810990</ArticleId><ArticleId IdType="pubmed">33452298</ArticleId></ArticleIdList></Reference><Reference><Citation>Corey K.M., Olson L.B., Naqvi I.A., Morrison S.A., Davis C., Nimjee S.M., Que L.G., Bachelder R.E., Kraft B.D., Chen L., et al. Suppression of Fibrinolysis and Hypercoagulability, Severity of Hypoxemia, and Mortality in COVID-19 Patients: A Retrospective Cohort Study. Anesthesiology. 2022;137:67&#x2013;78. doi: 10.1097/ALN.0000000000004239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0000000000004239</ArticleId><ArticleId IdType="pmc">PMC9250792</ArticleId><ArticleId IdType="pubmed">35412597</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetti M., Gomez-Rosas P., Russo L., Gamba S., Sanga E., Verzeroli C., Ambaglio C., Schieppati F., Restuccia F., Bonanomi E., et al. Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients. Front. Cardiovasc. Med. 2022;9:896362. doi: 10.3389/fcvm.2022.896362.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.896362</ArticleId><ArticleId IdType="pmc">PMC9226333</ArticleId><ArticleId IdType="pubmed">35757331</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Tamimi A.O., Yusuf A.M., Jayakumar M.N., Ansari A.W., Elhassan M., AbdulKarim F., Kannan M., Halwani R., Ahmad F. SARS-CoV-2 infection induces soluble platelet activation markers and PAI-1 in the early moderate stage of COVID-19. Int. J. Lab. Hematol. 2022;44:712&#x2013;721. doi: 10.1111/ijlh.13829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijlh.13829</ArticleId><ArticleId IdType="pmc">PMC9111479</ArticleId><ArticleId IdType="pubmed">35266284</ArticleId></ArticleIdList></Reference><Reference><Citation>Miltiades A.M., Houck P.J., Monteleone M., Harrison N.L., Cabrera-Garcia D., Roh D., Wagener G. Insights into Fibrinogen-Mediated COVID-19 Hypercoagubility in Critically Ill Patients. J. Neurosurg. Anesthesiol. 2021;34:136&#x2013;140. doi: 10.1097/ANA.0000000000000812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ANA.0000000000000812</ArticleId><ArticleId IdType="pubmed">34870637</ArticleId></ArticleIdList></Reference><Reference><Citation>Whyte C.S., Simpson M., Morrow G.B., Wallace C.A., Mentzer A.J., Knight J.C., Shapiro S., Curry N., Bagot C.N., Watson H., et al. The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1. J. Thromb. Haemost. 2022;20:2394&#x2013;2406. doi: 10.1111/jth.15806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15806</ArticleId><ArticleId IdType="pmc">PMC9349442</ArticleId><ArticleId IdType="pubmed">35780481</ArticleId></ArticleIdList></Reference><Reference><Citation>Whyte C.S., Morrow G.B., Mitchell J.L., Chowdary P., Mutch N.J. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J. Thromb. Haemost. 2020;18:1548&#x2013;1555. doi: 10.1111/jth.14872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14872</ArticleId><ArticleId IdType="pmc">PMC7264738</ArticleId><ArticleId IdType="pubmed">32329246</ArticleId></ArticleIdList></Reference><Reference><Citation>Arachchillage D.J., Remmington C., Rosenberg A., Xu T., Passariello M., Hall D., Laffan A.M., Patel B.V. Anticoagulation with argatroban in patients with acute antithrombin deficiency in severe COVID-19. Br. J. Haematol. 2020;190:e286&#x2013;e288. doi: 10.1111/bjh.16927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.16927</ArticleId><ArticleId IdType="pmc">PMC7300519</ArticleId><ArticleId IdType="pubmed">32516429</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri M., Ahamed J., Laurence J. Intervention in COVID-19 linked hypercoaguable states characterized by circuit thrombosis utilizing a direct thrombin inhibitor. Thromb. Update. 2020;1:100009. doi: 10.1016/j.tru.2020.100009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tru.2020.100009</ArticleId><ArticleId IdType="pmc">PMC7476895</ArticleId><ArticleId IdType="pubmed">38620488</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaller J., Gerber S.S. The plasmin&#x2013;antiplasmin system: Structural and functional aspects. Cell Mol. Life Sci. 2010;68:785&#x2013;801. doi: 10.1007/s00018-010-0566-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-010-0566-5</ArticleId><ArticleId IdType="pmc">PMC11115092</ArticleId><ArticleId IdType="pubmed">21136135</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Vlok M., Venter C., Bezuidenhout J.A., Laubscher G.J., Steenkamp J., Kell D.B. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc. Diabetol. 2021;20:172. doi: 10.1186/s12933-021-01359-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01359-7</ArticleId><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandoo A., van Zanten J.J., Metsios G.S., Carroll D., Kitas G.D. The endothelium and its role in regulating vascular tone. Open Cardiovasc. Med. J. 2010;4:302&#x2013;312. doi: 10.2174/1874192401004010302.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1874192401004010302</ArticleId><ArticleId IdType="pmc">PMC3040999</ArticleId><ArticleId IdType="pubmed">21339899</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan D., Frohlich S., McLoughlin P. Pulmonary vascular dysfunction in ARDS. Ann. Intensive Care. 2014;4:28. doi: 10.1186/s13613-014-0028-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-014-0028-6</ArticleId><ArticleId IdType="pmc">PMC4273697</ArticleId><ArticleId IdType="pubmed">25593744</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham G.R., Kuc R.E., Althage M., Greasley P.J., Ambery P., Maguire J.J., Wilkinson I.B., Hoole S.P., Cheriyan J., Davenport A.P. Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19. J. Mol. Cell Cardiol. 2022;167:92&#x2013;96. doi: 10.1016/j.yjmcc.2022.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2022.03.007</ArticleId><ArticleId IdType="pmc">PMC8941861</ArticleId><ArticleId IdType="pubmed">35339512</ArticleId></ArticleIdList></Reference><Reference><Citation>Miedema J., van der Sar-van der Brugge S., Schreurs M., Paats M., Baart S., Bakker M., Hoek R., Dik W.A., Endeman H., Van Der Velden V., et al. Antibodies Against Angiotensin II Receptor Type 1 and Endothelin A Receptor Are Associated with an Unfavorable COVID19 Disease Course. Front. Immunol. 2021;12:684142. doi: 10.3389/fimmu.2021.684142.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.684142</ArticleId><ArticleId IdType="pmc">PMC8155664</ArticleId><ArticleId IdType="pubmed">34054876</ArticleId></ArticleIdList></Reference><Reference><Citation>Jedlickova L., Merkovska L., Jackova L., Janicko M., Fedacko J., Novakova B., Chmelarova A., Majernik J., Pella D. Effect of Ivabradine on Endothelial Function in Patients with Stable Angina Pectoris: Assessment with the Endo-PAT 2000 Device. Adv. Ther. 2015;32:962&#x2013;970. doi: 10.1007/s12325-015-0253-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-015-0253-x</ArticleId><ArticleId IdType="pubmed">26525390</ArticleId></ArticleIdList></Reference><Reference><Citation>Benigni A., Cassis P., Remuzzi G. Angiotensin II revisited: New roles in inflammation, immunology and aging. EMBO Mol. Med. 2010;2:247&#x2013;257. doi: 10.1002/emmm.201000080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201000080</ArticleId><ArticleId IdType="pmc">PMC3377325</ArticleId><ArticleId IdType="pubmed">20597104</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagliaro P., Penna C. ACE/ACE2 Ratio: A Key Also in 2019 Coronavirus Disease (Covid-19)? Front. Med. 2020;7:335. doi: 10.3389/fmed.2020.00335.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00335</ArticleId><ArticleId IdType="pmc">PMC7314898</ArticleId><ArticleId IdType="pubmed">32626721</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers S., Bhatia M. ACE and ACE2 in Inflammation: A Tale of Two Enzymes. Inflamm. Allergy-Drug Targets. 2014;13:224&#x2013;234. doi: 10.2174/1871528113666140713164506.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871528113666140713164506</ArticleId><ArticleId IdType="pubmed">25019157</ArticleId></ArticleIdList></Reference><Reference><Citation>Maranduca M.A., Tanase D.M., Cozma C.T., Dima N., Clim A., Pinzariu A.C., Serban D.N., Serban I.L. The Impact of Angiotensin-Converting Enzyme-2/Angiotensin 1-7 Axis in Establishing Severe COVID-19 Consequences. Pharmaceutics. 2022;14:1906. doi: 10.3390/pharmaceutics14091906.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14091906</ArticleId><ArticleId IdType="pmc">PMC9505151</ArticleId><ArticleId IdType="pubmed">36145655</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy B., Fejes Z., Szentkereszty Z., S&#xfc;t&#x151; R., V&#xe1;rkonyi I., Ajzner &#xc9;., Kappelmayer J., Papp Z., T&#xf3;th A., Fagyas M. A dramatic rise in serum ACE2 activity in a critically ill COVID-19 patient. Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis. 2020;103:412&#x2013;414. doi: 10.1016/j.ijid.2020.11.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.11.184</ArticleId><ArticleId IdType="pmc">PMC7689308</ArticleId><ArticleId IdType="pubmed">33249290</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundstr&#xf6;m A., Ziegler L., Havervall S., Rudberg A., Meijenfeldt F., Lisman T., Mackman N., Sand&#xe9;n P., Th&#xe5;lin C. Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers. J. Med. Virol. 2021;93:5908&#x2013;5916. doi: 10.1002/jmv.27144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27144</ArticleId><ArticleId IdType="pmc">PMC8426677</ArticleId><ArticleId IdType="pubmed">34138483</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassiliou A.G., Zacharis A., Keskinidou C., Jahaj E., Pratikaki M., Gallos P., Dimopoulou I., Kotanidou A., Orfanos S.E. Soluble Angiotensin Converting Enzyme 2 (ACE2) Is Upregulated and Soluble Endothelial Nitric Oxide Synthase (eNOS) Is Downregulated in COVID-19-induced Acute Respiratory Distress Syndrome (ARDS) Pharmaceuticals. 2021;14:695. doi: 10.3390/ph14070695.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14070695</ArticleId><ArticleId IdType="pmc">PMC8308597</ArticleId><ArticleId IdType="pubmed">34358119</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman M.M., Hasan M., Ahmed A. Potential detrimental role of soluble ACE2 in severe COVID-19 comorbid patients. Rev. Med. Virol. 2021;31:1&#x2013;12. doi: 10.1002/rmv.2213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2213</ArticleId><ArticleId IdType="pmc">PMC8014495</ArticleId><ArticleId IdType="pubmed">33426683</ArticleId></ArticleIdList></Reference><Reference><Citation>Ipekci A., Biberoglu S., Ikizceli I., Cakmak F., Akdeniz Y.S., Kanbakan A., Konukoglu D., Bolayirli I.M., Borekci S., Urkmez S., et al. ACE2 and ANGII levels in patients with COVID-19 based on thoracic tomography findings and PCR test results. J. Infect. Dev. Ctries. 2022;16:427&#x2013;434. doi: 10.3855/jidc.15438.</Citation><ArticleIdList><ArticleId IdType="doi">10.3855/jidc.15438</ArticleId><ArticleId IdType="pubmed">35404847</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X., Li X., Trusa S., Olson S.C. Angiotensin type 1 receptor is linked to inhibition of nitric oxide production in pulmonary endothelial cells. Regul. Pept. 2005;132:113&#x2013;122. doi: 10.1016/j.regpep.2005.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.regpep.2005.09.010</ArticleId><ArticleId IdType="pubmed">16242794</ArticleId></ArticleIdList></Reference><Reference><Citation>Leowattana W., Leowattana T., Leowattana P. Circulating angiotensin converting enzyme 2 and COVID-19. World J. Clin. Cases. 2022;10:12470&#x2013;12483. doi: 10.12998/wjcc.v10.i34.12470.</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v10.i34.12470</ArticleId><ArticleId IdType="pmc">PMC9791519</ArticleId><ArticleId IdType="pubmed">36579082</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan K.K., Dorosky D., Sharma P., Abbasi S.A., Dye J.M., Kranz D.M., Herbert A.S., Procko E. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science. 2020;369:1261&#x2013;1265. doi: 10.1126/science.abc0870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc0870</ArticleId><ArticleId IdType="pmc">PMC7574912</ArticleId><ArticleId IdType="pubmed">32753553</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoufaly A., Poglitsch M., Aberle J.H., Hoepler W., Seitz T., Traugott M., Grieb A., Pawelka E., Laferl H., Wenisch C., et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir. Med. 2020;8:1154&#x2013;1158. doi: 10.1016/S2213-2600(20)30418-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30418-5</ArticleId><ArticleId IdType="pmc">PMC7515587</ArticleId><ArticleId IdType="pubmed">33131609</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnamurthy S., Lockey R.F., Kolliputi N. Soluble ACE2 as a potential therapy for COVID-19. Am. J. Physiol. Physiol. 2021;320:C279&#x2013;C281. doi: 10.1152/ajpcell.00478.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00478.2020</ArticleId><ArticleId IdType="pmc">PMC7938633</ArticleId><ArticleId IdType="pubmed">33502950</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z., Cai T., Fan L., Lou K., Hua X., Huang Z., Gao G. The potential role of serum angiotensin-converting enzyme in coronavirus disease 2019. BMC Infect. Dis. 2020;20:883. doi: 10.1186/s12879-020-05619-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-020-05619-x</ArticleId><ArticleId IdType="pmc">PMC7686943</ArticleId><ArticleId IdType="pubmed">33238910</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh N.I., Arowolo F., Durstenfeld M.S., Nah G., Njoroge J., Vittinghoff E., Long C.S., Ganz P., Pearce D., Hsue P., et al. Hospitalized Patients with COVID-19 Have Higher Plasma Aldosterone-Renin Ratio and Lower ACE Activity Than Controls. J. Endocr. Soc. 2022;6:bvac144. doi: 10.1210/jendso/bvac144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jendso/bvac144</ArticleId><ArticleId IdType="pmc">PMC9619433</ArticleId><ArticleId IdType="pubmed">36338506</ArticleId></ArticleIdList></Reference><Reference><Citation>Goren T., Yilmaz A., Uluturk M., Sabirli R., Kemanci A., Seyit M., Ozen M., Oskay A., Koseler A., Turkcuer I. Investigation of Serum Angiotensin-Converting Enzyme (ACE) Concentration and ACE Gene Polymorphism in Patients with SARS-CoV-2 Pneumonia Admitted to the Emergency Department. Cureus. 2022;14:e31201. doi: 10.7759/cureus.31201.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.31201</ArticleId><ArticleId IdType="pmc">PMC9728626</ArticleId><ArticleId IdType="pubmed">36505135</ArticleId></ArticleIdList></Reference><Reference><Citation>Guler A.A., Tombul N., Y&#x131;ld&#x131;z P.A., &#xd6;zger H.S., H&#x131;zel K., Gulbahar O., Tufan A., Erba&#x15f; G., Aygencel G., Tun&#xe7;can O.G., et al. The assessment of serum ACE activity in COVID-19 and its association with clinical features and severity of the disease. Scand. J. Clin. Lab. Investig. 2021;81:160&#x2013;165. doi: 10.1080/00365513.2021.1871641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365513.2021.1871641</ArticleId><ArticleId IdType="pmc">PMC7832453</ArticleId><ArticleId IdType="pubmed">33474994</ArticleId></ArticleIdList></Reference><Reference><Citation>Bueno V., Frasca D. Mini-review: Angiotensin- converting enzyme 1 (ACE1) and the impact for diseases such as Alzheimer&#x2019;s disease, sarcopenia, cancer, and COVID-19. Front. Aging. 2023;4:1117502. doi: 10.3389/fragi.2023.1117502.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fragi.2023.1117502</ArticleId><ArticleId IdType="pmc">PMC9899811</ArticleId><ArticleId IdType="pubmed">36756193</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Sayed Marei Y., Abdallah Bayoumy A., Mohamed Abulazm Nassar H., Mansour B., Bakeir Hamady A. The Relation between ACE Gene Polymorphism and the Severity of COVID-19 Infection. Int. J. Microbiol. 2023;2023:4540287. doi: 10.1155/2023/4540287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2023/4540287</ArticleId><ArticleId IdType="pmc">PMC9833908</ArticleId><ArticleId IdType="pubmed">36644496</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaei M., Mohammadpour H., Eftekhari M., Pourabdollah M., Azadani F.N., Tabarsi P., Marjani M., Ziai S.A. The role of angiotensin I converting enzyme insertion/deletion polymorphism in the severity and outcomes of COVID-19 patients. Front. Genet. 2022;13:1035796. doi: 10.3389/fgene.2022.1035796.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2022.1035796</ArticleId><ArticleId IdType="pmc">PMC9756080</ArticleId><ArticleId IdType="pubmed">36531237</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc5;kerstr&#xf6;m S., Mousavi-Jazi M., Klingstr&#xf6;m J., Leijon M., Lundkvist A., Mirazimi A. Nitric Oxide Inhibits the Replication Cycle of Severe Acute Respiratory Syndrome Coronavirus. J. Virol. 2005;79:1966&#x2013;1969. doi: 10.1128/JVI.79.3.1966-1969.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.3.1966-1969.2005</ArticleId><ArticleId IdType="pmc">PMC544093</ArticleId><ArticleId IdType="pubmed">15650225</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotz C., Muellenbach R.M., Meybohm P., Mutlak H., Lepper P.M., Rolfes C., Peivandi A., Stumpner J., Kredel M., Kranke P., et al. Effects of inhaled nitric oxide in COVID-19&#x2013;induced ARDS&#x2014;Is it worthwhile? Acta Anaesthesiol. Scand. 2020;65:629&#x2013;632. doi: 10.1111/aas.13757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aas.13757</ArticleId><ArticleId IdType="pubmed">33296498</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Sulaiman K., Korayem G.B., Altebainawi A.F., Al Harbi S., Alissa A., Alharthi A., Kensara R., Alfahed A., Vishwakarma R., Al Haji H., et al. Evaluation of inhaled nitric oxide (iNO) treatment for moderate-to-severe ARDS in critically ill patients with COVID-19: A multicenter cohort study. Crit. Care. 2022;26:304. doi: 10.1186/s13054-022-04158-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-022-04158-y</ArticleId><ArticleId IdType="pmc">PMC9527729</ArticleId><ArticleId IdType="pubmed">36192801</ArticleId></ArticleIdList></Reference><Reference><Citation>Longobardo A., Montanari C., Shulman R., Benhalim S., Singer M., Arulkumaran N. Inhaled nitric oxide minimally improves oxygenation in COVID-19 related acute respiratory distress syndrome. Br. J. Anaesth. 2020;126:e44&#x2013;e46. doi: 10.1016/j.bja.2020.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bja.2020.10.011</ArticleId><ArticleId IdType="pmc">PMC7556790</ArticleId><ArticleId IdType="pubmed">33138964</ArticleId></ArticleIdList></Reference><Reference><Citation>Poonam P.B.H., Koscik R., Nguyen T., Rikhi S., Lin H.-M. Nitric oxide versus epoprostenol for refractory hypoxemia in Covid-19. PLoS ONE. 2022;17:e0270646. doi: 10.1371/journal.pone.0270646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0270646</ArticleId><ArticleId IdType="pmc">PMC9236233</ArticleId><ArticleId IdType="pubmed">35759496</ArticleId></ArticleIdList></Reference><Reference><Citation>Kita T., Kitamura K. Adrenomedullin Therapy in Moderate to Severe COVID-19. Biomedicines. 2022;10:533. doi: 10.3390/biomedicines10030533.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10030533</ArticleId><ArticleId IdType="pmc">PMC8945653</ArticleId><ArticleId IdType="pubmed">35327335</ArticleId></ArticleIdList></Reference><Reference><Citation>Papasidero I.D., Valli G., Marin D., Del Sasso A., De Magistris A., Cennamo E., Casalboni S., De Marco F., Rocchi R., Beumo B.N., et al. Utility of Measuring Circulating Bio-Adrenomedullin and Proenkephalin for 30-Day Mortality Risk Prediction in Patients with COVID-19 and Non-COVID-19 Interstitial Pneumonia in the Emergency Department. Medicina. 2022;58:1852. doi: 10.3390/medicina58121852.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina58121852</ArticleId><ArticleId IdType="pmc">PMC9782909</ArticleId><ArticleId IdType="pubmed">36557054</ArticleId></ArticleIdList></Reference><Reference><Citation>de Montmollin E., Peoc&#x2019;h K., Marzouk M., Ruckly S., Wicky P.-H., Patrier J., Jaquet P., Sonneville R., Bouadma L., Timsit J.-F. Mid-Regional Pro-Adrenomedullin as a Prognostic Factor for Severe COVID-19 ARDS. Antibiotics. 2022;11:1166. doi: 10.3390/antibiotics11091166.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics11091166</ArticleId><ArticleId IdType="pmc">PMC9495198</ArticleId><ArticleId IdType="pubmed">36139946</ArticleId></ArticleIdList></Reference><Reference><Citation>Hupf J., Mustroph J., Hanses F., Evert K., Maier L.S., Jungbauer C.G. RNA-expression of adrenomedullin is increased in patients with severe COVID-19. Crit. Care. 2020;24:527. doi: 10.1186/s13054-020-03246-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03246-1</ArticleId><ArticleId IdType="pmc">PMC7453369</ArticleId><ArticleId IdType="pubmed">32859259</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon T.-P., Stoppe C., Breuer T., Stiehler L., Dreher M., Kersten A., Kluge S., Karakas M., Zechendorf E., Marx G., et al. Prognostic Value of Bioactive Adrenomedullin in Critically Ill Patients with COVID-19 in Germany: An Observational Cohort Study. J. Clin. Med. 2021;10:1667. doi: 10.3390/jcm10081667.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10081667</ArticleId><ArticleId IdType="pmc">PMC8069401</ArticleId><ArticleId IdType="pubmed">33924637</ArticleId></ArticleIdList></Reference><Reference><Citation>van Lier D., Deniau B., Santos K., Hartmann O., Dudoignon E., Depret F., Plaud B., Laterre P.-F., Mebazaa A., Pickkers P. Circulating dipeptidyl peptidase 3 and bio-adrenomedullin levels are associated with impaired outcomes in critically ill COVID-19 patients: A prospective international multicentre study. ERJ Open Res. 2022;9:00342. doi: 10.1183/23120541.00342-2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00342-2022</ArticleId><ArticleId IdType="pmc">PMC9571166</ArticleId><ArticleId IdType="pubmed">36628268</ArticleId></ArticleIdList></Reference><Reference><Citation>Karakas M., Jarczak D., Becker M., Roedl K., Addo M.M., Hein F., Bergmann A., Zimmermann J., Simon T.-P., Marx G., et al. Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101) Biomolecules. 2020;10:1171. doi: 10.3390/biom10081171.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10081171</ArticleId><ArticleId IdType="pmc">PMC7465983</ArticleId><ArticleId IdType="pubmed">32796765</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>